{"messages":[{"status":"ok","cursor":"990","count":30,"total":9467}], "collection":[{"rel_doi":"10.1101\/2020.09.07.286666","rel_title":"UVA radiation could be a significant contributor to sunlight inactivation of SARS-CoV-2","rel_date":"2020-09-08","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.09.07.286666","rel_abs":"Past experiments demonstrated SARS-CoV-2 inactivation by simulated sunlight; models have considered exclusively mechanisms involving UVB acting directly on RNA. However, UVA inactivation has been demonstrated for other enveloped RNA viruses, through indirect mechanisms involving the suspension medium. We propose a model combining UVB and UVA inactivation for SARS-CoV-2, which improves predictions by accounting for effects associated with the medium. UVA sensitivities deduced for SARS-CoV-2 are consistent with data for SARS-CoV-1 under UVA only. This analysis calls for experiments to separately assess effects of UVA and UVB in different media, and for including UVA in inactivation models.\n\nLay summaryRecent experiments have demonstrated that SARS-CoV-2 is inactivated by simulated sunlight; however, there are still many unknowns, including the mechanism of action and which part of the light spectrum is principally responsible. Our analysis indicates the need for targeted experiments that can separately assess the effects of UVA and UVB on SARS-CoV-2, and that sunlight inactivation models may need to be expanded to also include the effect of UVA. A first UVA-inclusive model is also proposed here. These findings have implications for how to improve the safety of the built environment, and for the seasonality of COVID-19.","rel_num_authors":6,"rel_authors":[{"author_name":"Paolo Luzzatto-Fegiz","author_inst":"University of California, Santa Barbara"},{"author_name":"Fernando Temprano-Coleto","author_inst":"University of California Santa Barbara"},{"author_name":"Francois J Peaudecerf","author_inst":"Institute for Environmental Engineering, ETH Zurich, Switzerland"},{"author_name":"Julien R Landel","author_inst":"Department of Mathematics, University of Manchester, UK"},{"author_name":"Yangying Zhu","author_inst":"Department of Mechanical Engineering, University of California, Santa Barbara, CA, USA"},{"author_name":"Julie A McMurry","author_inst":"Oregon State University"}],"version":"1","license":"cc_by","type":"new results","category":"biochemistry"},{"rel_doi":"10.1101\/2020.09.08.287201","rel_title":"Analysis of SARS-CoV-2 genomes from across Africa reveals potentially clinically relevant mutations.","rel_date":"2020-09-08","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.09.08.287201","rel_abs":"SARS-CoV-2 is a betacoronavirus, the etiologic agent of the novel Coronavirus disease 2019 (COVID-19). The World Health Organization officially declared COVID-19 as a pandemic in March 2020 after the outbreak in Wuhan, China, in late 2019. Across the continents and specifically in Africa, all index cases were travel-related. Understanding how the viruss transportation across continents and different climatic conditions affect the genetic composition and the consequent effects on transmissibility, infectivity, and virulence of the virus is critical. Thus, it is crucial to compare COVID-19 genome sequences from the African continent with sequences from selected COVID-19 hotspots\/countries in Asia, Europe, North and South America and Oceania.\n\nTo identify possible distinguishing mutations in the African SARS-CoV-2 genomes compared to those from these selected countries, we conducted in silico analyses and comparisons. Complete African SARS-CoV-2 genomes deposited in GISAID and NCBI databases as of June 2020 were downloaded and aligned with genomes from Wuhan, China and other SARS-CoV-2 hotspots. Using phylogenetic analysis and amino acid sequence alignments of the spike and replicase (NSP12) proteins, we searched for possible vaccine coverage targets or potential therapeutic agents. Identity plots for the alignments were created with BioEdit software and the phylogenetic analyses with the MEGA X software.\n\nOur results showed mutations in the spike and replicate proteins of the SARS-Cov-2 virus. Phylogenetic tree analyses demonstrated variability across the various regions\/countries in Africa as there were different clades in the viral proteins. However, a substantial proportion of these mutations (90%) were similar to those described in all the other settings, including the Wuhan strain. There were, however, novel mutations in the genomes of the circulating strains of the virus in African. To the best of our knowledge, this is the first study reporting these findings from Africa. However, these findings implications on symptomatic or asymptomatic manifestations, progression to severe disease and case fatality for those affected, and the cross efficacy of vaccines developed from other settings when applied in Africa are unknown.","rel_num_authors":9,"rel_authors":[{"author_name":"Modeline Nicholas Longjohn","author_inst":"Department of Biochemistry, Memorial University of Newfoundland, Newfoundland and Labrador, Canada."},{"author_name":"Olivia S. Egbule","author_inst":"Department of Microbiology, Delta State University, Abraka, Delta State, Nigeria"},{"author_name":"Samuel O Danso","author_inst":"University of Edinburgh Medical School, Scotland, United Kingdom"},{"author_name":"Eugene Akujuru","author_inst":"Department of Haematology, Blood Transfusion and Immunology, University of Port Harcourt, Rivers State, Nigeria."},{"author_name":"Victor T Ibubeleye","author_inst":"African Centre for Excellence in Public Health and Toxicological Research University of Port Harcourt, Rivers State, Nigeria."},{"author_name":"Christabel I Oweredaba","author_inst":"School of Science, Engineering and Environment, University of Salford, United Kingdom."},{"author_name":"Theodora Ogharanduku","author_inst":"Department of Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom"},{"author_name":"Alexander Manu","author_inst":"Centre for Maternal & Newborn Health, Liverpool School of Tropical Medicine, Liverpool, United Kingdom"},{"author_name":"Benson C. Iweriebor","author_inst":"Safako Makgatho Health Sciences University, Pretoria, South Africa"}],"version":"1","license":"cc_by_nd","type":"new results","category":"bioinformatics"},{"rel_doi":"10.1101\/2020.09.08.280818","rel_title":"A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates","rel_date":"2020-09-08","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.09.08.280818","rel_abs":"To contain the coronavirus disease 2019 (COVID-19) pandemic, a safe and effective vaccine against the new severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is urgently needed in quantities sufficient to immunise large populations. In this study, we report the design, preclinical development, immunogenicity and anti-viral protective effect in rhesus macaques of the BNT162b2 vaccine candidate. BNT162b2 contains an LNP-formulated nucleoside-modified mRNA that encodes the spike glycoprotein captured in its prefusion conformation. After expression of the BNT162b2 coding sequence in cells, approximately 20% of the spike molecules are in the one-RBD  up, two-RBD  down state. Immunisation of mice with a single dose of BNT162b2 induced dose level-dependent increases in pseudovirus neutralisation titers. Prime-boost vaccination of rhesus macaques elicited authentic SARS-CoV-2 neutralising geometric mean titers 10.2 to 18.0 times that of a SARS-CoV-2 convalescent human serum panel. BNT162b2 generated strong TH1 type CD4+ and IFN{gamma}+ CD8+ T-cell responses in mice and rhesus macaques. The BNT162b2 vaccine candidate fully protected the lungs of immunised rhesus macaques from infectious SARS-CoV-2 challenge. BNT162b2 is currently being evaluated in a global, pivotal Phase 2\/3 trial (NCT04368728).","rel_num_authors":61,"rel_authors":[{"author_name":"Annette Vogel","author_inst":"BioNTech RNA Pharmaceuticals GmbH"},{"author_name":"Isis Kanevsky","author_inst":"Pfizer inc."},{"author_name":"Ye Che","author_inst":"Pfizer Inc."},{"author_name":"Kena Swanson","author_inst":"Pfizer Inc."},{"author_name":"Alexander Muik","author_inst":"BioNTech RNA Pharmaceuticals GmbH"},{"author_name":"Mathias Vormehr","author_inst":"BioNTech RNA Pharmaceuticals GmbH"},{"author_name":"Lena Kranz","author_inst":"BioNTech RNA Pharmaceuticals GmbH"},{"author_name":"Kerstin Walzer","author_inst":"BioNTech SE"},{"author_name":"Stephanie Hein","author_inst":"BioNTech RNA Pharmaceuticals GmbH"},{"author_name":"Alptekin Gueler","author_inst":"BioNTech RNA Pharmaceuticals GmbH"},{"author_name":"Jakob Loschko","author_inst":"Pfizer Inc."},{"author_name":"Mohan Maddur","author_inst":"Pfizer Inc."},{"author_name":"Kristin Tompkins","author_inst":"Pfizer Inc."},{"author_name":"Journey Cole","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Bonny Gaby Lui","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Thomas Ziegenhals","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Arianne Plaschke","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"David Eisel","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Sarah Dany","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Stephanie Fesser","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Stephanie Erbar","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"ferdia Bates","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Diana Schneider","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Bernadette Jesionek","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Bianca Saenger","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Ann-Kathrin Wallisch","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Yvonne Feuchter","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Hanna Junginger","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Stefanie Krumm","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Andre Heinen","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Petra Adams-Quack","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Julia Schlereth","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Christoph Kroener","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Shannan Hall-Ursone","author_inst":"University of Texas Medical Branch"},{"author_name":"Kathleen Brasky","author_inst":"University of Texas Medical Branch"},{"author_name":"Matthew C Griffor","author_inst":"Pfizer Inc."},{"author_name":"Seungil Han","author_inst":"Pfizer Inc"},{"author_name":"Joshua Lees","author_inst":"Pfizer Inc."},{"author_name":"Ellene Mashalidis","author_inst":"Pfizer Inc."},{"author_name":"Parag Sahasrabudhe","author_inst":"Pfizer Inc."},{"author_name":"Charles Tan","author_inst":"Pfizer Inc."},{"author_name":"Danka Pavliakova","author_inst":"Pfizer Inc."},{"author_name":"Guy Singh","author_inst":"Pfizer Inc."},{"author_name":"Camila Fontes-Garfias","author_inst":"University of Texas Medical Branch"},{"author_name":"Michael Pride","author_inst":"Pfizer Inc."},{"author_name":"Ingrid Scully","author_inst":"Pfizer Inc."},{"author_name":"tara Ciolino","author_inst":"Pfizer Inc."},{"author_name":"Jennifer Obregon","author_inst":"Pfizer Inc."},{"author_name":"Michal Gazi","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Ricardo Carrion","author_inst":"University of Texas Medical Branch"},{"author_name":"Kendra Alfson","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Warren Kalina","author_inst":"Pfizer Inc."},{"author_name":"Deepak Kaushal","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Thorsten Klamp","author_inst":"BioNTech SE"},{"author_name":"Corinna Rosenbaum","author_inst":"BioNTech SE"},{"author_name":"Andreas Kuhn","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech SE"},{"author_name":"Philip Dormitzer","author_inst":"Pfizer Inc."},{"author_name":"Kathrin Jansen","author_inst":"Pfizer Inc."},{"author_name":"Ugur Sahin","author_inst":"BioNTech SE"}],"version":"1","license":"cc_no","type":"new results","category":"immunology"},{"rel_doi":"10.1101\/2020.09.08.287482","rel_title":"Antibody binding to SARS-CoV-2 S glycoprotein correlates with, but does not predict neutralization","rel_date":"2020-09-08","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.09.08.287482","rel_abs":"Convalescent plasma from SARS-CoV-2 infected individuals and monoclonal antibodies were shown to potently neutralize viral and pseudoviral particles carrying the S glycoprotein. However, a non-negligent proportion of plasma samples from infected individuals as well as S-specific monoclonal antibodies were reported to be non-neutralizing despite efficient interaction with the S glycoprotein in different biochemical assays using soluble recombinant forms of S or when expressed at the cell surface. How neutralization relates to binding of S glycoprotein in the context of viral particles remains to be established. Here we developed a pseudovirus capture assay (VCA) to measure the capacity of plasma samples or antibodies immobilized on ELISA plates to bind to membrane-bound S glycoproteins from SARS-CoV-2 expressed at the surface of lentiviral particles. By performing VCA and neutralization assays we observed a strong correlation between these two parameters. However, while we found that plasma samples unable to capture viral particles did not neutralize, capture did not guarantee neutralization, indicating that the capacity of antibodies to bind to the S glycoprotein at the surface of viral particles is required but not sufficient to mediate neutralization. Altogether, our results highlights the importance of better understanding the inactivation of S by plasma and neutralizing antibodies.","rel_num_authors":9,"rel_authors":[{"author_name":"Shilei Ding","author_inst":"CRCHUM"},{"author_name":"Annemarie Laumaea","author_inst":"Universite de Montreal"},{"author_name":"Romain Gasser","author_inst":"Universite de Montreal"},{"author_name":"Halima Medjahed","author_inst":"CRCHUM"},{"author_name":"Marie Pancera","author_inst":"Fred Hutchinson Cancer Research Center"},{"author_name":"Leonidas Stamatatos","author_inst":"Fred Hutchinson Cancer Research Center"},{"author_name":"Andrew McGuire","author_inst":"Fred Hutchinson Cancer Research Center"},{"author_name":"Renee Bazin","author_inst":"Hema-Quebec"},{"author_name":"Andres Finzi","author_inst":"Universite de Montreal"},{"author_name":"Alptekin Gueler","author_inst":"BioNTech RNA Pharmaceuticals GmbH"},{"author_name":"Jakob Loschko","author_inst":"Pfizer Inc."},{"author_name":"Mohan Maddur","author_inst":"Pfizer Inc."},{"author_name":"Kristin Tompkins","author_inst":"Pfizer Inc."},{"author_name":"Journey Cole","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Bonny Gaby Lui","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Thomas Ziegenhals","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Arianne Plaschke","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"David Eisel","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Sarah Dany","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Stephanie Fesser","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Stephanie Erbar","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"ferdia Bates","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Diana Schneider","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Bernadette Jesionek","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Bianca Saenger","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Ann-Kathrin Wallisch","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Yvonne Feuchter","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Hanna Junginger","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Stefanie Krumm","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Andre Heinen","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Petra Adams-Quack","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Julia Schlereth","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Christoph Kroener","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Shannan Hall-Ursone","author_inst":"University of Texas Medical Branch"},{"author_name":"Kathleen Brasky","author_inst":"University of Texas Medical Branch"},{"author_name":"Matthew C Griffor","author_inst":"Pfizer Inc."},{"author_name":"Seungil Han","author_inst":"Pfizer Inc"},{"author_name":"Joshua Lees","author_inst":"Pfizer Inc."},{"author_name":"Ellene Mashalidis","author_inst":"Pfizer Inc."},{"author_name":"Parag Sahasrabudhe","author_inst":"Pfizer Inc."},{"author_name":"Charles Tan","author_inst":"Pfizer Inc."},{"author_name":"Danka Pavliakova","author_inst":"Pfizer Inc."},{"author_name":"Guy Singh","author_inst":"Pfizer Inc."},{"author_name":"Camila Fontes-Garfias","author_inst":"University of Texas Medical Branch"},{"author_name":"Michael Pride","author_inst":"Pfizer Inc."},{"author_name":"Ingrid Scully","author_inst":"Pfizer Inc."},{"author_name":"tara Ciolino","author_inst":"Pfizer Inc."},{"author_name":"Jennifer Obregon","author_inst":"Pfizer Inc."},{"author_name":"Michal Gazi","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Ricardo Carrion","author_inst":"University of Texas Medical Branch"},{"author_name":"Kendra Alfson","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Warren Kalina","author_inst":"Pfizer Inc."},{"author_name":"Deepak Kaushal","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Thorsten Klamp","author_inst":"BioNTech SE"},{"author_name":"Corinna Rosenbaum","author_inst":"BioNTech SE"},{"author_name":"Andreas Kuhn","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech SE"},{"author_name":"Philip Dormitzer","author_inst":"Pfizer Inc."},{"author_name":"Kathrin Jansen","author_inst":"Pfizer Inc."},{"author_name":"Ugur Sahin","author_inst":"BioNTech SE"}],"version":"1","license":"cc_no","type":"new results","category":"microbiology"},{"rel_doi":"10.1101\/2020.09.07.286906","rel_title":"In vitro study of BromAc on SARS-CoV-2 spike and envelope proteins shows synergy and disintegration at modest concentrations","rel_date":"2020-09-08","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.09.07.286906","rel_abs":"ObjectivesSARS-CoV-2 infection is the cause of a worldwide pandemic, currently with limited therapeutic options. It is characterised by being highly contagious and nasal mucosa appears to be the primary site with subsequent spread to the lungs and elsewhere. BromAc (Bromelain & Acetylcysteine) has been described to disrupt glycoproteins by the synchronous breakage of glycosidic linkages and disulphide bonds. The spike protein of SARS-CoV-2 is an attractive target as it is essential for binding to the ACE2 receptor in host cells and is formed of glycoprotein and disulphide bridges for stabilisation. Hence, we sought to determine whether BromAc has activity on the spike and envelope protein specific to SARS-CoV-2 virus.\n\nDesignGel electrophoresis analysis was carried out on recombinant spike and envelope proteins that were treated with a range of concentrations of single agents and BromAc. For UV analysis of disulfide bonds reduction, both spike and envelope protein were treated with Acetylcysteine with the determination of loss of disulfide bonds.\n\nResultsRecombinant spike and envelope SARS-CoV-2 protein were fragmented by BromAc whilst single agents had minimal effect. Spike and envelope proteins disulphide bonds were reduced by Acetylcysteine.\n\nConclusionBromAc disintegrates the spike and envelope protein from SARS-CoV-2 and may render it non-infective. In vitro tests on live virus have been encouraging and clinical testing through nasal administration in patients with early SARS-CoV-2 infection is imminent.","rel_num_authors":6,"rel_authors":[{"author_name":"Javed Akhter","author_inst":"St George Hospital"},{"author_name":"Krishna Pillai","author_inst":"St George Hospital"},{"author_name":"Samina Badar","author_inst":"UNSW"},{"author_name":"Ahmed Mekkawy","author_inst":"UNSW"},{"author_name":"Sarah Valle","author_inst":"UNSW"},{"author_name":"David L Morris","author_inst":"University of New South Wales, St George Hospital"},{"author_name":"Andrew McGuire","author_inst":"Fred Hutchinson Cancer Research Center"},{"author_name":"Renee Bazin","author_inst":"Hema-Quebec"},{"author_name":"Andres Finzi","author_inst":"Universite de Montreal"},{"author_name":"Alptekin Gueler","author_inst":"BioNTech RNA Pharmaceuticals GmbH"},{"author_name":"Jakob Loschko","author_inst":"Pfizer Inc."},{"author_name":"Mohan Maddur","author_inst":"Pfizer Inc."},{"author_name":"Kristin Tompkins","author_inst":"Pfizer Inc."},{"author_name":"Journey Cole","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Bonny Gaby Lui","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Thomas Ziegenhals","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Arianne Plaschke","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"David Eisel","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Sarah Dany","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Stephanie Fesser","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Stephanie Erbar","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"ferdia Bates","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Diana Schneider","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Bernadette Jesionek","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Bianca Saenger","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Ann-Kathrin Wallisch","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Yvonne Feuchter","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Hanna Junginger","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Stefanie Krumm","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Andre Heinen","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Petra Adams-Quack","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Julia Schlereth","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Christoph Kroener","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Shannan Hall-Ursone","author_inst":"University of Texas Medical Branch"},{"author_name":"Kathleen Brasky","author_inst":"University of Texas Medical Branch"},{"author_name":"Matthew C Griffor","author_inst":"Pfizer Inc."},{"author_name":"Seungil Han","author_inst":"Pfizer Inc"},{"author_name":"Joshua Lees","author_inst":"Pfizer Inc."},{"author_name":"Ellene Mashalidis","author_inst":"Pfizer Inc."},{"author_name":"Parag Sahasrabudhe","author_inst":"Pfizer Inc."},{"author_name":"Charles Tan","author_inst":"Pfizer Inc."},{"author_name":"Danka Pavliakova","author_inst":"Pfizer Inc."},{"author_name":"Guy Singh","author_inst":"Pfizer Inc."},{"author_name":"Camila Fontes-Garfias","author_inst":"University of Texas Medical Branch"},{"author_name":"Michael Pride","author_inst":"Pfizer Inc."},{"author_name":"Ingrid Scully","author_inst":"Pfizer Inc."},{"author_name":"tara Ciolino","author_inst":"Pfizer Inc."},{"author_name":"Jennifer Obregon","author_inst":"Pfizer Inc."},{"author_name":"Michal Gazi","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Ricardo Carrion","author_inst":"University of Texas Medical Branch"},{"author_name":"Kendra Alfson","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Warren Kalina","author_inst":"Pfizer Inc."},{"author_name":"Deepak Kaushal","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Thorsten Klamp","author_inst":"BioNTech SE"},{"author_name":"Corinna Rosenbaum","author_inst":"BioNTech SE"},{"author_name":"Andreas Kuhn","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech SE"},{"author_name":"Philip Dormitzer","author_inst":"Pfizer Inc."},{"author_name":"Kathrin Jansen","author_inst":"Pfizer Inc."},{"author_name":"Ugur Sahin","author_inst":"BioNTech SE"}],"version":"1","license":"cc_no","type":"new results","category":"microbiology"},{"rel_doi":"10.1101\/2020.09.07.286567","rel_title":"Interaction of human ACE2 to membrane-bound SARS-CoV-1 and SARS-CoV-2 S glycoproteins","rel_date":"2020-09-08","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.09.07.286567","rel_abs":"A novel severe acute respiratory (SARS)-like coronavirus (SARS-CoV-2) is responsible for the current global coronavirus disease 2019 (COVID-19) pandemic, infecting millions of people and causing hundreds of thousands of deaths. The viral entry of SARS-CoV-2 depends on an interaction between the receptor binding domain of its trimeric Spike glycoprotein and the human angiotensin converting enzyme 2 (ACE2) receptor. A better understanding of the Spike\/ACE2 interaction is still required to design anti-SARS-CoV-2 therapeutics. Here, we investigated the degree of cooperativity of ACE2 within both the SARS-CoV-2 and the closely related SARS-CoV-1 membrane-bound S glycoproteins. We show that there exist differential inter-protomer conformational transitions between both Spike trimers. Interestingly, the SARS-CoV-2 spike exhibits a positive cooperativity for monomeric soluble ACE2 binding when compared to the SARS-CoV-1 spike, which might have more structural restrains. Our findings can be of importance in the development of therapeutics that block the Spike\/ACE2 interaction.","rel_num_authors":8,"rel_authors":[{"author_name":"Sai Priya Anand","author_inst":"CRCHUM \/ McGill University"},{"author_name":"Yaozong Chen","author_inst":"USUHS"},{"author_name":"Jeremie Prevost","author_inst":"CRCHUM \/ Universite de Montreal"},{"author_name":"Romain Gasser","author_inst":"CRCHUM \/ Universite de Montreal"},{"author_name":"Guillaume Beaudoin-Bussieres","author_inst":"CRCHUM \/ Universite de Montreal"},{"author_name":"Cameron F Abrams","author_inst":"Drexel University"},{"author_name":"Marzena Pazgier","author_inst":"USUHS"},{"author_name":"Andres Finzi","author_inst":"CRCHUM \/ Universite de Montreal"},{"author_name":"Andres Finzi","author_inst":"Universite de Montreal"},{"author_name":"Alptekin Gueler","author_inst":"BioNTech RNA Pharmaceuticals GmbH"},{"author_name":"Jakob Loschko","author_inst":"Pfizer Inc."},{"author_name":"Mohan Maddur","author_inst":"Pfizer Inc."},{"author_name":"Kristin Tompkins","author_inst":"Pfizer Inc."},{"author_name":"Journey Cole","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Bonny Gaby Lui","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Thomas Ziegenhals","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Arianne Plaschke","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"David Eisel","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Sarah Dany","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Stephanie Fesser","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Stephanie Erbar","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"ferdia Bates","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Diana Schneider","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Bernadette Jesionek","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Bianca Saenger","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Ann-Kathrin Wallisch","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Yvonne Feuchter","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Hanna Junginger","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Stefanie Krumm","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Andre Heinen","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Petra Adams-Quack","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Julia Schlereth","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Christoph Kroener","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Shannan Hall-Ursone","author_inst":"University of Texas Medical Branch"},{"author_name":"Kathleen Brasky","author_inst":"University of Texas Medical Branch"},{"author_name":"Matthew C Griffor","author_inst":"Pfizer Inc."},{"author_name":"Seungil Han","author_inst":"Pfizer Inc"},{"author_name":"Joshua Lees","author_inst":"Pfizer Inc."},{"author_name":"Ellene Mashalidis","author_inst":"Pfizer Inc."},{"author_name":"Parag Sahasrabudhe","author_inst":"Pfizer Inc."},{"author_name":"Charles Tan","author_inst":"Pfizer Inc."},{"author_name":"Danka Pavliakova","author_inst":"Pfizer Inc."},{"author_name":"Guy Singh","author_inst":"Pfizer Inc."},{"author_name":"Camila Fontes-Garfias","author_inst":"University of Texas Medical Branch"},{"author_name":"Michael Pride","author_inst":"Pfizer Inc."},{"author_name":"Ingrid Scully","author_inst":"Pfizer Inc."},{"author_name":"tara Ciolino","author_inst":"Pfizer Inc."},{"author_name":"Jennifer Obregon","author_inst":"Pfizer Inc."},{"author_name":"Michal Gazi","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Ricardo Carrion","author_inst":"University of Texas Medical Branch"},{"author_name":"Kendra Alfson","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Warren Kalina","author_inst":"Pfizer Inc."},{"author_name":"Deepak Kaushal","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Thorsten Klamp","author_inst":"BioNTech SE"},{"author_name":"Corinna Rosenbaum","author_inst":"BioNTech SE"},{"author_name":"Andreas Kuhn","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech SE"},{"author_name":"Philip Dormitzer","author_inst":"Pfizer Inc."},{"author_name":"Kathrin Jansen","author_inst":"Pfizer Inc."},{"author_name":"Ugur Sahin","author_inst":"BioNTech SE"}],"version":"1","license":"cc_no","type":"new results","category":"microbiology"},{"rel_doi":"10.1101\/2020.09.04.20188268","rel_title":"The link between vitamin D deficiency and Covid-19 in a large population","rel_date":"2020-09-07","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.09.04.20188268","rel_abs":"BACKGROUND Recent studies suggest a link between vitamin D deficiency and Covid-19 infection. In our population we observe major differences in Covid-19 incidence in ethnic groups and genders in each group. METHODS We carried out a population-based study among 4.6 million members of Clalit Health Services (CHS). We collected results from vitamin D tests performed between 2010 and 2019 and used weighted linear regression to assess the relationship between prevalence of vitamin D deficiency and Covid-19 incidence in 200 localities. Additionally, we matched 52,405 infected patients with 524,050 control individuals of the same sex, age, geographical region and used conditional logistic regression to assess the relationship between baseline vitamin D levels, acquisition of vitamin D supplements in the last 4 months, and positive Covid-19. RESULTS We observe a highly significant correlation between prevalence of vitamin D deficiency and Covid-19 incidence, and between female-to-male ratio for severe vitamin D deficiency and female-to-male ratio for Covid-19 incidence in localities (P<0.001). In the matched cohort, we found a significant association between low vitamin D levels and the risk of Covid-19, with the highest risk observed for severe vitamin D deficiency. A significant protective effect was observed for members who acquired liquid vitamin D formulations (drops) in the last 4 months. CONCLUSION In this large observational population study, we show a strong association between vitamin D deficiency and Covid-19 occurrence. After adjustment for baseline characteristics and prior vitamin D levels, acquisition of liquid vitamin D formulations is associated with decreased risk for Covid-19 infection.","rel_num_authors":8,"rel_authors":[{"author_name":"Ariel Israel","author_inst":"Clalit Health Services"},{"author_name":"Assi Albert Cicurel","author_inst":"Clalit Health Services"},{"author_name":"Ilan Feldhamer","author_inst":"Clalit Health Services"},{"author_name":"Yosef Dror","author_inst":"The Faculty of Agriculture, The Hebrew University of Jerusalem"},{"author_name":"Shmuel M Giveon","author_inst":"Clalit Health Services"},{"author_name":"David Gillis","author_inst":"Hadassah-Hebrew University Medical Center, Jerusalem"},{"author_name":"David Strich","author_inst":"Clalit Health services, Jerusalem District"},{"author_name":"Gil Lavie","author_inst":"Clalit Health Services"},{"author_name":"Andres Finzi","author_inst":"Universite de Montreal"},{"author_name":"Alptekin Gueler","author_inst":"BioNTech RNA Pharmaceuticals GmbH"},{"author_name":"Jakob Loschko","author_inst":"Pfizer Inc."},{"author_name":"Mohan Maddur","author_inst":"Pfizer Inc."},{"author_name":"Kristin Tompkins","author_inst":"Pfizer Inc."},{"author_name":"Journey Cole","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Bonny Gaby Lui","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Thomas Ziegenhals","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Arianne Plaschke","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"David Eisel","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Sarah Dany","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Stephanie Fesser","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Stephanie Erbar","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"ferdia Bates","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Diana Schneider","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Bernadette Jesionek","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Bianca Saenger","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Ann-Kathrin Wallisch","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Yvonne Feuchter","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Hanna Junginger","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Stefanie Krumm","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Andre Heinen","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Petra Adams-Quack","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Julia Schlereth","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Christoph Kroener","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Shannan Hall-Ursone","author_inst":"University of Texas Medical Branch"},{"author_name":"Kathleen Brasky","author_inst":"University of Texas Medical Branch"},{"author_name":"Matthew C Griffor","author_inst":"Pfizer Inc."},{"author_name":"Seungil Han","author_inst":"Pfizer Inc"},{"author_name":"Joshua Lees","author_inst":"Pfizer Inc."},{"author_name":"Ellene Mashalidis","author_inst":"Pfizer Inc."},{"author_name":"Parag Sahasrabudhe","author_inst":"Pfizer Inc."},{"author_name":"Charles Tan","author_inst":"Pfizer Inc."},{"author_name":"Danka Pavliakova","author_inst":"Pfizer Inc."},{"author_name":"Guy Singh","author_inst":"Pfizer Inc."},{"author_name":"Camila Fontes-Garfias","author_inst":"University of Texas Medical Branch"},{"author_name":"Michael Pride","author_inst":"Pfizer Inc."},{"author_name":"Ingrid Scully","author_inst":"Pfizer Inc."},{"author_name":"tara Ciolino","author_inst":"Pfizer Inc."},{"author_name":"Jennifer Obregon","author_inst":"Pfizer Inc."},{"author_name":"Michal Gazi","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Ricardo Carrion","author_inst":"University of Texas Medical Branch"},{"author_name":"Kendra Alfson","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Warren Kalina","author_inst":"Pfizer Inc."},{"author_name":"Deepak Kaushal","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Thorsten Klamp","author_inst":"BioNTech SE"},{"author_name":"Corinna Rosenbaum","author_inst":"BioNTech SE"},{"author_name":"Andreas Kuhn","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech SE"},{"author_name":"Philip Dormitzer","author_inst":"Pfizer Inc."},{"author_name":"Kathrin Jansen","author_inst":"Pfizer Inc."},{"author_name":"Ugur Sahin","author_inst":"BioNTech SE"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.09.04.20188094","rel_title":"Regression Models for Predictions of COVID-19 New Cases and New Deaths Based on May\/June Data in Ethiopia","rel_date":"2020-09-07","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.09.04.20188094","rel_abs":"As the 15 of June 2020, we have 7,984,067 total COVID-19 cases, globally and 435,181 total deaths. Ethiopia was ranked 2nd and 15th in the table by 176 new cases and by 3,521 total new cases from African countries. Then, this study aimed to predict COVID-19 new cases and new deaths based on May\/June data in Ethiopia using regression model. In this study, I used Pearson correlation analysis and the linear regression model to predict COVID-19 new cases and new deaths based on the available data from 12th May to 10th June 2020 in Ethiopia. There was a significant positive correlation between COVID-19 new cases and new deaths with different related variables. In the regression models, the simple linear regression model was a better fit the data of COVID-19 new cases and new deaths than as compared with quadratic and cubic regression models. In the multiple linear regression model, variables such as the number of days, the number of new laboratory tests, and the number of new cases from AA city significantly predicted the COVID-19 new cases. In this model, the number of days and new recoveries significantly predicted new deaths of COVID-19. The number of days, daily laboratory tests, and new cases from Addis Ababa city significantly predicted new COVID-19 cases, and the number of days and new recoveries significantly predicted new deaths from COVID-19. According to this analysis, if strong preventions and action are not taken in the country, the predicted values of COVID-19 new cases and new deaths will be 590 and 12 after two months (after 9th of August) from now, respectively. The researcher recommended that the Ethiopia government, Ministry of Health and Addis Ababa city administrative should give more awareness and protections for societies, and they should also open more COVID-19 laboratory testing centers. Generally, the obtained results of this study may help Ethiopian decision-makers put short-term future plans to face this epidemic.","rel_num_authors":1,"rel_authors":[{"author_name":"Alemayehu Siffir Argawu Sr.","author_inst":"Ambo University"},{"author_name":"Assi Albert Cicurel","author_inst":"Clalit Health Services"},{"author_name":"Ilan Feldhamer","author_inst":"Clalit Health Services"},{"author_name":"Yosef Dror","author_inst":"The Faculty of Agriculture, The Hebrew University of Jerusalem"},{"author_name":"Shmuel M Giveon","author_inst":"Clalit Health Services"},{"author_name":"David Gillis","author_inst":"Hadassah-Hebrew University Medical Center, Jerusalem"},{"author_name":"David Strich","author_inst":"Clalit Health services, Jerusalem District"},{"author_name":"Gil Lavie","author_inst":"Clalit Health Services"},{"author_name":"Andres Finzi","author_inst":"Universite de Montreal"},{"author_name":"Alptekin Gueler","author_inst":"BioNTech RNA Pharmaceuticals GmbH"},{"author_name":"Jakob Loschko","author_inst":"Pfizer Inc."},{"author_name":"Mohan Maddur","author_inst":"Pfizer Inc."},{"author_name":"Kristin Tompkins","author_inst":"Pfizer Inc."},{"author_name":"Journey Cole","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Bonny Gaby Lui","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Thomas Ziegenhals","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Arianne Plaschke","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"David Eisel","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Sarah Dany","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Stephanie Fesser","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Stephanie Erbar","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"ferdia Bates","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Diana Schneider","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Bernadette Jesionek","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Bianca Saenger","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Ann-Kathrin Wallisch","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Yvonne Feuchter","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Hanna Junginger","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Stefanie Krumm","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Andre Heinen","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Petra Adams-Quack","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Julia Schlereth","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Christoph Kroener","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Shannan Hall-Ursone","author_inst":"University of Texas Medical Branch"},{"author_name":"Kathleen Brasky","author_inst":"University of Texas Medical Branch"},{"author_name":"Matthew C Griffor","author_inst":"Pfizer Inc."},{"author_name":"Seungil Han","author_inst":"Pfizer Inc"},{"author_name":"Joshua Lees","author_inst":"Pfizer Inc."},{"author_name":"Ellene Mashalidis","author_inst":"Pfizer Inc."},{"author_name":"Parag Sahasrabudhe","author_inst":"Pfizer Inc."},{"author_name":"Charles Tan","author_inst":"Pfizer Inc."},{"author_name":"Danka Pavliakova","author_inst":"Pfizer Inc."},{"author_name":"Guy Singh","author_inst":"Pfizer Inc."},{"author_name":"Camila Fontes-Garfias","author_inst":"University of Texas Medical Branch"},{"author_name":"Michael Pride","author_inst":"Pfizer Inc."},{"author_name":"Ingrid Scully","author_inst":"Pfizer Inc."},{"author_name":"tara Ciolino","author_inst":"Pfizer Inc."},{"author_name":"Jennifer Obregon","author_inst":"Pfizer Inc."},{"author_name":"Michal Gazi","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Ricardo Carrion","author_inst":"University of Texas Medical Branch"},{"author_name":"Kendra Alfson","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Warren Kalina","author_inst":"Pfizer Inc."},{"author_name":"Deepak Kaushal","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Thorsten Klamp","author_inst":"BioNTech SE"},{"author_name":"Corinna Rosenbaum","author_inst":"BioNTech SE"},{"author_name":"Andreas Kuhn","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech SE"},{"author_name":"Philip Dormitzer","author_inst":"Pfizer Inc."},{"author_name":"Kathrin Jansen","author_inst":"Pfizer Inc."},{"author_name":"Ugur Sahin","author_inst":"BioNTech SE"}],"version":"1","license":"cc_by","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.09.04.20188102","rel_title":"Modeling COVID-19 Transmission in Africa: Country-wise Projections of Total and Severe Infections Under Different Lockdown Scenarios","rel_date":"2020-09-07","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.09.04.20188102","rel_abs":"Objectives As of August 24th 2020, there have been 1,084,904 confirmed cases of SARS-CoV-2 and 24,683 deaths across the African continent. Despite relatively lower numbers of cases initially, many African countries are now experiencing an exponential increase in case numbers. Estimates of the progression of disease and potential impact of different interventions are needed to inform policy making decisions. Herein, we model the possible trajectory of SARS-CoV-2 in 52 African countries under different intervention scenarios. Design We developed a compartmental model of SARS-CoV-2 transmission to estimate the COVID-19 case burden for all African countries while considering four scenarios: no intervention, moderate lockdown, hard lockdown, and hard lockdown with continued restrictions once lockdown is lifted. We further analyzed the potential impact of COVID-19 on vulnerable populations affected by HIV\/AIDS and TB. Results In the absence of an intervention, the most populous countries had the highest peaks in active projected number of infections with Nigeria having an estimated 645,081 severe infections. The scenario with a hard lockdown and continued post-lockdown interventions to reduce transmission was the most efficacious strategy for delaying the time to the peak and reducing the number of cases. In South Africa projected peak severe infections increase from 162,977 to 203,261, when vulnerable populations with HIV\/AIDS and TB are included in the analysis. Conclusion The COVID-19 pandemic is rapidly spreading across the African continent. Estimates of the potential impact of interventions and burden of disease are essential for policy makers to make evidence-based decisions on the distribution of limited resources and to balance the economic costs of interventions with the potential for saving lives.","rel_num_authors":11,"rel_authors":[{"author_name":"Isabel Frost","author_inst":"Center for Disease Dynamics Economics & Policy"},{"author_name":"Jessica Craig","author_inst":"CDDEP"},{"author_name":"Gilbert Osena","author_inst":"Center for Disease Dynamics, Economics & Policy"},{"author_name":"Stephanie Hauck","author_inst":"Center for Disease Dynamics Economics & Policy"},{"author_name":"Erta Kalanxhi","author_inst":"Center for Disease Dynamics Economics & Policy"},{"author_name":"Emily Schueller","author_inst":"Center for Disease Dynamics Economics & Policy"},{"author_name":"Oliver Gatalo","author_inst":"Center for Disease Dynamics Economics & Policy"},{"author_name":"Yupeng Yany","author_inst":"Center for Disease Dynamics Economics & Policy"},{"author_name":"Katie Tseng","author_inst":"Center for Disease Dynamics Economics & Policy"},{"author_name":"Gary Lin","author_inst":"Johns Hopkins University"},{"author_name":"Eili Klein","author_inst":"Center for Disease Dynamics Economics & Policy"},{"author_name":"Mohan Maddur","author_inst":"Pfizer Inc."},{"author_name":"Kristin Tompkins","author_inst":"Pfizer Inc."},{"author_name":"Journey Cole","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Bonny Gaby Lui","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Thomas Ziegenhals","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Arianne Plaschke","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"David Eisel","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Sarah Dany","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Stephanie Fesser","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Stephanie Erbar","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"ferdia Bates","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Diana Schneider","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Bernadette Jesionek","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Bianca Saenger","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Ann-Kathrin Wallisch","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Yvonne Feuchter","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Hanna Junginger","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Stefanie Krumm","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Andre Heinen","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Petra Adams-Quack","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Julia Schlereth","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Christoph Kroener","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Shannan Hall-Ursone","author_inst":"University of Texas Medical Branch"},{"author_name":"Kathleen Brasky","author_inst":"University of Texas Medical Branch"},{"author_name":"Matthew C Griffor","author_inst":"Pfizer Inc."},{"author_name":"Seungil Han","author_inst":"Pfizer Inc"},{"author_name":"Joshua Lees","author_inst":"Pfizer Inc."},{"author_name":"Ellene Mashalidis","author_inst":"Pfizer Inc."},{"author_name":"Parag Sahasrabudhe","author_inst":"Pfizer Inc."},{"author_name":"Charles Tan","author_inst":"Pfizer Inc."},{"author_name":"Danka Pavliakova","author_inst":"Pfizer Inc."},{"author_name":"Guy Singh","author_inst":"Pfizer Inc."},{"author_name":"Camila Fontes-Garfias","author_inst":"University of Texas Medical Branch"},{"author_name":"Michael Pride","author_inst":"Pfizer Inc."},{"author_name":"Ingrid Scully","author_inst":"Pfizer Inc."},{"author_name":"tara Ciolino","author_inst":"Pfizer Inc."},{"author_name":"Jennifer Obregon","author_inst":"Pfizer Inc."},{"author_name":"Michal Gazi","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Ricardo Carrion","author_inst":"University of Texas Medical Branch"},{"author_name":"Kendra Alfson","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Warren Kalina","author_inst":"Pfizer Inc."},{"author_name":"Deepak Kaushal","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Thorsten Klamp","author_inst":"BioNTech SE"},{"author_name":"Corinna Rosenbaum","author_inst":"BioNTech SE"},{"author_name":"Andreas Kuhn","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech SE"},{"author_name":"Philip Dormitzer","author_inst":"Pfizer Inc."},{"author_name":"Kathrin Jansen","author_inst":"Pfizer Inc."},{"author_name":"Ugur Sahin","author_inst":"BioNTech SE"}],"version":"1","license":"cc_by","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.09.01.20184390","rel_title":"Convalescent plasma as potential therapy for severe COVID-19 pneumonia.","rel_date":"2020-09-07","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.09.01.20184390","rel_abs":"At the beginning of the COVID-19 pandemic, there was high mortality and a lack of effective treatment for critically ill patients. Build on the experience in argentine hemorrhagic fever with convalescent plasma, we incorporated 90 patients into a multicenter study, and 87 were evaluable. We collected 397 donations from 278 convalescent donors. Patients received plasma with an IgG concentration of 0.7-0.8 (measured by Abbott chemiluminescence) for every 10 kg of body weight. Survival during the first 28 days was the primary objective. 77% were male, age 54 (+\/-15.6 y\/o (range 27-85); body mass index 29.7 +\/-; 4,4; hypertension 39% and diabetes 20%; 19.5% had an immunosuppression condition; 23% were healthcare workers. Plasma was administered to 55 patients (63%) on spontaneous breathing with oxygen supplementation (mainly oxygen mask with reservoir bag in 80%), and 32 patients (37%) were infused on mechanical ventilation. The 28-day survival rate was 80%, with 91% in patients infused on spontaneous breathing and 63% in those infused on mechanical ventilation (p = 0.0002). There was a significant improvement in the WHO pneumonia clinical scale at 7 and 14 days, and in PaO2 \/ FiO2, ferritin and LDH, in the week post-infusion. We observed an episode of circulatory volume overload and a febrile reaction, both mild. Convalescent plasma infusions are feasible, safe, and potentially effective, especially before requiring mechanical ventilation, and are an attractive clinical option for treating severe forms of COVID-19 until other effective therapies become available.","rel_num_authors":16,"rel_authors":[{"author_name":"Ricardo Valentini","author_inst":"Centro de Educacion Medica e Investigaciones Clinicas"},{"author_name":"Juan Dupont","author_inst":"Centro de Educacion Medica e Investigaciones Clinicas (CEMIC)"},{"author_name":"Jose Fernandez","author_inst":"Centro de Educacion Medica e Investigaciones Clinicas (CEMIC)"},{"author_name":"Jorge Solimano","author_inst":"Centro de Educacion Medica e Investigaciones Clinicas (CEMIC)"},{"author_name":"Fernando Palizas","author_inst":"Sanatorio Guemes"},{"author_name":"Dardo Riveros","author_inst":"Centro de Educacion Medica e Investigaciones Clinicas (CEMIC)"},{"author_name":"Pablo Saul","author_inst":"Policlinico Union Obrera Metalurgica"},{"author_name":"Laura Dupont","author_inst":"Instituto Universitario CEMIC"},{"author_name":"Juan Medina","author_inst":"Sanatorio Itoitz"},{"author_name":"Viviana Falasco","author_inst":"Hospital Pedro Fiorito"},{"author_name":"Florencia Fornillo","author_inst":"Instituto Universitario CEMIC"},{"author_name":"Julia Laviano","author_inst":"Instituto Universitario CEMIC"},{"author_name":"Daniela Maymo","author_inst":"Instituto Universitario CEMIC"},{"author_name":"Daniel Gotta","author_inst":"Centro de Educacion Medica e Investigaciones Clinicas (CEMIC)"},{"author_name":"Alfredo Martinez","author_inst":"Centro de Educacion Medica e Investigaciones Clinicas (CEMIC)"},{"author_name":"Pablo Bonvehi","author_inst":"Centro de Educacion Medica e Investigaciones Clinicas (CEMIC)"},{"author_name":"Arianne Plaschke","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"David Eisel","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Sarah Dany","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Stephanie Fesser","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Stephanie Erbar","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"ferdia Bates","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Diana Schneider","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Bernadette Jesionek","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Bianca Saenger","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Ann-Kathrin Wallisch","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Yvonne Feuchter","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Hanna Junginger","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Stefanie Krumm","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Andre Heinen","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Petra Adams-Quack","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Julia Schlereth","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Christoph Kroener","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Shannan Hall-Ursone","author_inst":"University of Texas Medical Branch"},{"author_name":"Kathleen Brasky","author_inst":"University of Texas Medical Branch"},{"author_name":"Matthew C Griffor","author_inst":"Pfizer Inc."},{"author_name":"Seungil Han","author_inst":"Pfizer Inc"},{"author_name":"Joshua Lees","author_inst":"Pfizer Inc."},{"author_name":"Ellene Mashalidis","author_inst":"Pfizer Inc."},{"author_name":"Parag Sahasrabudhe","author_inst":"Pfizer Inc."},{"author_name":"Charles Tan","author_inst":"Pfizer Inc."},{"author_name":"Danka Pavliakova","author_inst":"Pfizer Inc."},{"author_name":"Guy Singh","author_inst":"Pfizer Inc."},{"author_name":"Camila Fontes-Garfias","author_inst":"University of Texas Medical Branch"},{"author_name":"Michael Pride","author_inst":"Pfizer Inc."},{"author_name":"Ingrid Scully","author_inst":"Pfizer Inc."},{"author_name":"tara Ciolino","author_inst":"Pfizer Inc."},{"author_name":"Jennifer Obregon","author_inst":"Pfizer Inc."},{"author_name":"Michal Gazi","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Ricardo Carrion","author_inst":"University of Texas Medical Branch"},{"author_name":"Kendra Alfson","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Warren Kalina","author_inst":"Pfizer Inc."},{"author_name":"Deepak Kaushal","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Thorsten Klamp","author_inst":"BioNTech SE"},{"author_name":"Corinna Rosenbaum","author_inst":"BioNTech SE"},{"author_name":"Andreas Kuhn","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech SE"},{"author_name":"Philip Dormitzer","author_inst":"Pfizer Inc."},{"author_name":"Kathrin Jansen","author_inst":"Pfizer Inc."},{"author_name":"Ugur Sahin","author_inst":"BioNTech SE"}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.09.04.20187849","rel_title":"Association between population density and infection rate suggests the importance of social distancing and travel restriction in reducing the COVID-19 pandemic","rel_date":"2020-09-07","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.09.04.20187849","rel_abs":"Background: Currently, the 2019-nCoV has spread to most countries of the world. Understanding the environmental factors that affect the spread of the disease COVID-19 infection is critical to stop the spread of the disease. The purpose of this study is to investigate whether population density is associated with the infection rate of the COVID-19. Methods: We collected data from official webpages of cities in China and in the US. The data were uploaded on Excel spreadsheets for statistical analyses. We calculated the morbidity and population density of cities and regions in these two countries. We then examined the relationship between the morbidity and other factors. Results: Our analysis indicated that the population density in cities in Hubei province where the COVID-19 was severe was associated with a higher percentage of morbidity, with an r value of 0.62. Similarly, in the US, the density of 51 states and territories is also associated with morbidity from COVID-19 with an r value of 0.55. In contrast, as a control group, there is no association between the morbidity and population density in 33 other regions of China, where the COVID-19 epidemic is well under control. Interestingly, our study also indicated that these associations were not influenced by the first case of COVID-19. The rate of morbidity and the number of days from the first case in the US has no association, with an r value of -0.1288. Conclusions: Population density is positively associated with the percentage of patients with COVID-19 infection in the population. Our data support the importance of such as social distancing and travel restriction in the prevention of COVID-19 spread.","rel_num_authors":11,"rel_authors":[{"author_name":"Heliang Yin","author_inst":"Center of Integrative Research, The First Hospital of Qiqihar City, Qiqihar, Heilongjiang 161005, P.R. China."},{"author_name":"Tong Sun","author_inst":"Department of Administration, The First Hospital of Qiqihar, Qiqihar, Heilongjiang, 161005, P.R. China."},{"author_name":"Lan Yao","author_inst":"Health Outcomes and Policy Research, College of Graduate Health Sciences, University of Tennessee Health Science Center, Memphis, TN 38103, USA."},{"author_name":"Yan Jiao","author_inst":"Department of Orthopedic Surgery and BME-Campbell Clinic, University of Tennessee Health Science Center, Memphis, Tennessee, 38163, USA."},{"author_name":"Ma Li","author_inst":"Center of Integrative Research, The First Hospital of Qiqihar City, Qiqihar, Heilongjiang 161005, P.R. China."},{"author_name":"Lin Lin","author_inst":"Center of Integrative Research, The First Hospital of Qiqihar City, Qiqihar, Heilongjiang 161005, P.R. China."},{"author_name":"J Carolyn Graff","author_inst":"College of Nursing, University of Tennessee Health Science Center, Memphis, TN 38105, USA."},{"author_name":"Lotfi Aleya","author_inst":"Chrono-Environnement Laboratory, UMR CNRS 6249, Bourgogne Franche-Comte University, F-25030 Besancon Cedex, France"},{"author_name":"Arnold Postlethwaite","author_inst":"Department of Medicine and Division of Connective Tissue Diseases, University of Tennessee Health Science Center, Memphis, Tennessee, 38163, USA"},{"author_name":"Weikuan Gu","author_inst":"Research Service, Memphis VA Medical Center, 1030 Jefferson Avenue, Memphis, TN, 38104, USA."},{"author_name":"Hong Chen","author_inst":"Center of Integrative Research, The First Hospital of Qiqihar City, Qiqihar, Heilongjiang 161005, P.R. China."},{"author_name":"Julia Laviano","author_inst":"Instituto Universitario CEMIC"},{"author_name":"Daniela Maymo","author_inst":"Instituto Universitario CEMIC"},{"author_name":"Daniel Gotta","author_inst":"Centro de Educacion Medica e Investigaciones Clinicas (CEMIC)"},{"author_name":"Alfredo Martinez","author_inst":"Centro de Educacion Medica e Investigaciones Clinicas (CEMIC)"},{"author_name":"Pablo Bonvehi","author_inst":"Centro de Educacion Medica e Investigaciones Clinicas (CEMIC)"},{"author_name":"Arianne Plaschke","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"David Eisel","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Sarah Dany","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Stephanie Fesser","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Stephanie Erbar","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"ferdia Bates","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Diana Schneider","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Bernadette Jesionek","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Bianca Saenger","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Ann-Kathrin Wallisch","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Yvonne Feuchter","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Hanna Junginger","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Stefanie Krumm","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Andre Heinen","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Petra Adams-Quack","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Julia Schlereth","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Christoph Kroener","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Shannan Hall-Ursone","author_inst":"University of Texas Medical Branch"},{"author_name":"Kathleen Brasky","author_inst":"University of Texas Medical Branch"},{"author_name":"Matthew C Griffor","author_inst":"Pfizer Inc."},{"author_name":"Seungil Han","author_inst":"Pfizer Inc"},{"author_name":"Joshua Lees","author_inst":"Pfizer Inc."},{"author_name":"Ellene Mashalidis","author_inst":"Pfizer Inc."},{"author_name":"Parag Sahasrabudhe","author_inst":"Pfizer Inc."},{"author_name":"Charles Tan","author_inst":"Pfizer Inc."},{"author_name":"Danka Pavliakova","author_inst":"Pfizer Inc."},{"author_name":"Guy Singh","author_inst":"Pfizer Inc."},{"author_name":"Camila Fontes-Garfias","author_inst":"University of Texas Medical Branch"},{"author_name":"Michael Pride","author_inst":"Pfizer Inc."},{"author_name":"Ingrid Scully","author_inst":"Pfizer Inc."},{"author_name":"tara Ciolino","author_inst":"Pfizer Inc."},{"author_name":"Jennifer Obregon","author_inst":"Pfizer Inc."},{"author_name":"Michal Gazi","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Ricardo Carrion","author_inst":"University of Texas Medical Branch"},{"author_name":"Kendra Alfson","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Warren Kalina","author_inst":"Pfizer Inc."},{"author_name":"Deepak Kaushal","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Thorsten Klamp","author_inst":"BioNTech SE"},{"author_name":"Corinna Rosenbaum","author_inst":"BioNTech SE"},{"author_name":"Andreas Kuhn","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech SE"},{"author_name":"Philip Dormitzer","author_inst":"Pfizer Inc."},{"author_name":"Kathrin Jansen","author_inst":"Pfizer Inc."},{"author_name":"Ugur Sahin","author_inst":"BioNTech SE"}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"epidemiology"},{"rel_doi":"10.1101\/2020.09.04.20186569","rel_title":"Parents' and guardians' views and experiences of accessing routine childhood vaccinations during the coronavirus (COVID-19) pandemic: A mixed methods study in England","rel_date":"2020-09-07","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.09.04.20186569","rel_abs":"Objective: To explore parents' and guardians' views and experiences of accessing National Health Service (NHS) general practices for routine childhood vaccinations during the coronavirus (COVID-19) pandemic in England. Design: Mixed methods approach involving an online cross-sectional survey (conducted between 19th April and 11th May 2020) and semi-structured telephone interviews (conducted between 27th April and 27th May 2020). Participants: 1252 parents and guardians (aged 16+ years) who reported living in England with a child aged 18 months or under completed the survey. Nineteen survey respondents took part in follow-up interviews. Results: The majority of survey respondents (85.7%) considered it important for their children to receive routine vaccinations on schedule during the COVID-19 pandemic; however, several barriers to vaccination were identified. These included a lack of clarity around whether vaccination services were operating as usual, particularly amongst respondents from lower income households and those self-reporting as Black, Asian, Chinese, Mixed or Other ethnicity; difficulties in organising vaccination appointments; and fears around contracting COVID-19 while attending general practice. Concerns about catching COVID-19 while accessing general practice were weighed against concerns about children acquiring a vaccine-preventable disease if they did not receive scheduled routine childhood vaccinations. Many parents and guardians felt their child's risk of acquiring a vaccine-preventable disease was low as the implementation of stringent physical distancing measures (from March 23rd 2020) meant they were not mixing with others. Conclusion: To promote routine childhood vaccination uptake during the current COVID-19 outbreak, further waves of COVID-19 infection, and future pandemics, prompt and sustained national and general practice level communication is needed to raise awareness of vaccination service continuation and the importance of timely vaccination, and invitation-reminder systems for vaccination need to be maintained. To allay concerns about the safety of accessing general practice, practices should communicate the measures being implemented to prevent COVID-19 transmission.","rel_num_authors":4,"rel_authors":[{"author_name":"Sadie L Bell","author_inst":"London School of Hygiene and Tropical Medicine"},{"author_name":"Richard Clarke","author_inst":"Newcastle University London"},{"author_name":"Pauline Paterson","author_inst":"London School of Hygiene and Tropical Medicine"},{"author_name":"Sandra Mounier-Jack","author_inst":"London School of Hygiene and Tropical Medicine"},{"author_name":"Ma Li","author_inst":"Center of Integrative Research, The First Hospital of Qiqihar City, Qiqihar, Heilongjiang 161005, P.R. China."},{"author_name":"Lin Lin","author_inst":"Center of Integrative Research, The First Hospital of Qiqihar City, Qiqihar, Heilongjiang 161005, P.R. China."},{"author_name":"J Carolyn Graff","author_inst":"College of Nursing, University of Tennessee Health Science Center, Memphis, TN 38105, USA."},{"author_name":"Lotfi Aleya","author_inst":"Chrono-Environnement Laboratory, UMR CNRS 6249, Bourgogne Franche-Comte University, F-25030 Besancon Cedex, France"},{"author_name":"Arnold Postlethwaite","author_inst":"Department of Medicine and Division of Connective Tissue Diseases, University of Tennessee Health Science Center, Memphis, Tennessee, 38163, USA"},{"author_name":"Weikuan Gu","author_inst":"Research Service, Memphis VA Medical Center, 1030 Jefferson Avenue, Memphis, TN, 38104, USA."},{"author_name":"Hong Chen","author_inst":"Center of Integrative Research, The First Hospital of Qiqihar City, Qiqihar, Heilongjiang 161005, P.R. China."},{"author_name":"Julia Laviano","author_inst":"Instituto Universitario CEMIC"},{"author_name":"Daniela Maymo","author_inst":"Instituto Universitario CEMIC"},{"author_name":"Daniel Gotta","author_inst":"Centro de Educacion Medica e Investigaciones Clinicas (CEMIC)"},{"author_name":"Alfredo Martinez","author_inst":"Centro de Educacion Medica e Investigaciones Clinicas (CEMIC)"},{"author_name":"Pablo Bonvehi","author_inst":"Centro de Educacion Medica e Investigaciones Clinicas (CEMIC)"},{"author_name":"Arianne Plaschke","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"David Eisel","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Sarah Dany","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Stephanie Fesser","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Stephanie Erbar","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"ferdia Bates","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Diana Schneider","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Bernadette Jesionek","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Bianca Saenger","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Ann-Kathrin Wallisch","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Yvonne Feuchter","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Hanna Junginger","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Stefanie Krumm","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Andre Heinen","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Petra Adams-Quack","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Julia Schlereth","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Christoph Kroener","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Shannan Hall-Ursone","author_inst":"University of Texas Medical Branch"},{"author_name":"Kathleen Brasky","author_inst":"University of Texas Medical Branch"},{"author_name":"Matthew C Griffor","author_inst":"Pfizer Inc."},{"author_name":"Seungil Han","author_inst":"Pfizer Inc"},{"author_name":"Joshua Lees","author_inst":"Pfizer Inc."},{"author_name":"Ellene Mashalidis","author_inst":"Pfizer Inc."},{"author_name":"Parag Sahasrabudhe","author_inst":"Pfizer Inc."},{"author_name":"Charles Tan","author_inst":"Pfizer Inc."},{"author_name":"Danka Pavliakova","author_inst":"Pfizer Inc."},{"author_name":"Guy Singh","author_inst":"Pfizer Inc."},{"author_name":"Camila Fontes-Garfias","author_inst":"University of Texas Medical Branch"},{"author_name":"Michael Pride","author_inst":"Pfizer Inc."},{"author_name":"Ingrid Scully","author_inst":"Pfizer Inc."},{"author_name":"tara Ciolino","author_inst":"Pfizer Inc."},{"author_name":"Jennifer Obregon","author_inst":"Pfizer Inc."},{"author_name":"Michal Gazi","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Ricardo Carrion","author_inst":"University of Texas Medical Branch"},{"author_name":"Kendra Alfson","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Warren Kalina","author_inst":"Pfizer Inc."},{"author_name":"Deepak Kaushal","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Thorsten Klamp","author_inst":"BioNTech SE"},{"author_name":"Corinna Rosenbaum","author_inst":"BioNTech SE"},{"author_name":"Andreas Kuhn","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech SE"},{"author_name":"Philip Dormitzer","author_inst":"Pfizer Inc."},{"author_name":"Kathrin Jansen","author_inst":"Pfizer Inc."},{"author_name":"Ugur Sahin","author_inst":"BioNTech SE"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"primary care research"},{"rel_doi":"10.1101\/2020.09.04.20187971","rel_title":"Strategies for exiting COVID-19 lockdown for workplace and school: a scoping review protocol","rel_date":"2020-09-07","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.09.04.20187971","rel_abs":"Objective: The main objectives of this review are to summarise the existing literature and to identify strategies for exiting lockdown during the COVID-19 pandemic, with a focus on reopening schools and returning to work. Introduction: After months of strict quarantine, several countries are planning exit strategies to progressively lift social restrictions without giving rise to an increase in the number of COVID-19 cases. Although several strategies have been studied in terms of how and when to relax such stringent constraints, there is a lack of consensus on the optimal strategy for managing the pandemic beyond lockdown. The risks posed by delaying return to work and school openings are real and sizeable, particularly for relevant working sectors and for students from low-income families Inclusion criteria: This review will consider studies that focussed on relaxation strategies for lockdown exit among workers and students facing an epidemic \/pandemic crisis. Methods: The searches will be conducted across four databases (MEDLINE, EMBASE, SciSearch, Google Scholar), and the bibliography of all selected studies will be hand-searched. In addition, because the topic is new, relevant literature will be checked using daily, updated COVID-19 collections from NCBI (LitCovid) and MedRxiv servers. Studies published in English, German, Spanish, Italian and French will be included, with no limits on publication dates. This review will consider all study designs, regardless of their rigor. The review method will be based on a two-phase approach: a title and abstract screening, and a full-text review performed by two independent researchers. Data will be summarised and categorised, and results will be presented in a tabular\/diagrammatic form.","rel_num_authors":8,"rel_authors":[{"author_name":"Daniela D'Angelo Sr.","author_inst":"National Center of Clinical Excellence, Healthcare Quality and Safety (CNEC), National Institute of Health, Rome, Italy"},{"author_name":"Daniela Coclite Sr.","author_inst":"National Center of Clinical Excellence, Healthcare Quality and Safety (CNEC), National Institute of Health, Rome, Italy"},{"author_name":"Antonello Napoletano Sr.","author_inst":"National Center of Clinical Excellence, Healthcare Quality and Safety (CNEC), National Institute of Health, Rome, Italy"},{"author_name":"Alice Josephine Fauci Sr.","author_inst":"National Center of Clinical Excellence, Healthcare Quality and Safety (CNEC), National Institute of Health, Rome, Italy"},{"author_name":"Roberto Latina Sr.","author_inst":"National Center of Clinical Excellence, Healthcare Quality and Safety (CNEC), National Institute of Health, Rome, Italy"},{"author_name":"Laura Iacorossi Sr.","author_inst":"National Center of Clinical Excellence, Healthcare Quality and Safety (CNEC), National Institute of Health, Rome, Italy"},{"author_name":"Marco Di Nitto Sr.","author_inst":"Department of Biomedicine and Prevention, University of Rome Tor Vergata. Rome, Italy"},{"author_name":"Primiano Iannone Sr.","author_inst":"National Center of Clinical Excellence, Healthcare Quality and Safety (CNEC), National Institute of Health, Rome, Italy"},{"author_name":"Arnold Postlethwaite","author_inst":"Department of Medicine and Division of Connective Tissue Diseases, University of Tennessee Health Science Center, Memphis, Tennessee, 38163, USA"},{"author_name":"Weikuan Gu","author_inst":"Research Service, Memphis VA Medical Center, 1030 Jefferson Avenue, Memphis, TN, 38104, USA."},{"author_name":"Hong Chen","author_inst":"Center of Integrative Research, The First Hospital of Qiqihar City, Qiqihar, Heilongjiang 161005, P.R. China."},{"author_name":"Julia Laviano","author_inst":"Instituto Universitario CEMIC"},{"author_name":"Daniela Maymo","author_inst":"Instituto Universitario CEMIC"},{"author_name":"Daniel Gotta","author_inst":"Centro de Educacion Medica e Investigaciones Clinicas (CEMIC)"},{"author_name":"Alfredo Martinez","author_inst":"Centro de Educacion Medica e Investigaciones Clinicas (CEMIC)"},{"author_name":"Pablo Bonvehi","author_inst":"Centro de Educacion Medica e Investigaciones Clinicas (CEMIC)"},{"author_name":"Arianne Plaschke","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"David Eisel","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Sarah Dany","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Stephanie Fesser","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Stephanie Erbar","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"ferdia Bates","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Diana Schneider","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Bernadette Jesionek","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Bianca Saenger","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Ann-Kathrin Wallisch","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Yvonne Feuchter","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Hanna Junginger","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Stefanie Krumm","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Andre Heinen","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Petra Adams-Quack","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Julia Schlereth","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Christoph Kroener","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Shannan Hall-Ursone","author_inst":"University of Texas Medical Branch"},{"author_name":"Kathleen Brasky","author_inst":"University of Texas Medical Branch"},{"author_name":"Matthew C Griffor","author_inst":"Pfizer Inc."},{"author_name":"Seungil Han","author_inst":"Pfizer Inc"},{"author_name":"Joshua Lees","author_inst":"Pfizer Inc."},{"author_name":"Ellene Mashalidis","author_inst":"Pfizer Inc."},{"author_name":"Parag Sahasrabudhe","author_inst":"Pfizer Inc."},{"author_name":"Charles Tan","author_inst":"Pfizer Inc."},{"author_name":"Danka Pavliakova","author_inst":"Pfizer Inc."},{"author_name":"Guy Singh","author_inst":"Pfizer Inc."},{"author_name":"Camila Fontes-Garfias","author_inst":"University of Texas Medical Branch"},{"author_name":"Michael Pride","author_inst":"Pfizer Inc."},{"author_name":"Ingrid Scully","author_inst":"Pfizer Inc."},{"author_name":"tara Ciolino","author_inst":"Pfizer Inc."},{"author_name":"Jennifer Obregon","author_inst":"Pfizer Inc."},{"author_name":"Michal Gazi","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Ricardo Carrion","author_inst":"University of Texas Medical Branch"},{"author_name":"Kendra Alfson","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Warren Kalina","author_inst":"Pfizer Inc."},{"author_name":"Deepak Kaushal","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Thorsten Klamp","author_inst":"BioNTech SE"},{"author_name":"Corinna Rosenbaum","author_inst":"BioNTech SE"},{"author_name":"Andreas Kuhn","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech SE"},{"author_name":"Philip Dormitzer","author_inst":"Pfizer Inc."},{"author_name":"Kathrin Jansen","author_inst":"Pfizer Inc."},{"author_name":"Ugur Sahin","author_inst":"BioNTech SE"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"public and global health"},{"rel_doi":"10.1101\/2020.09.04.20188185","rel_title":"Efficacy assessment of newly-designed and locally-produced filtering facemasks during the SARS-CoV-2 pandemic.","rel_date":"2020-09-07","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.09.04.20188185","rel_abs":"The SARS-CoV-2 pandemic resulted in shortages of production and test capacity of FFP2-respirators. Such facemasks are required to be worn by healthcare professionals when performing aerosol-generating procedures on COVID-19 patients. In response to the high demand and short supply, we designed three models of facemasks that are suitable for local production. As these facemasks should meet the requirements of an FFP2-certified facemask, the newly-designed facemasks were tested on the filtration efficiency of the filter material, inward leakage, and breathing resistance with custom-made experimental setups. In these tests, the locally-produced facemasks were benchmarked against a commercial FFP2 facemask. Furthermore, the protective capacity of the facemasks was tested for the first time with coronavirus-loaded aerosols under physiologically relevant conditions. This multidisciplinary effort resulted in the design and production of facemasks that meet the FFP2 requirements, and which can be mass-produced at local production facilities.","rel_num_authors":10,"rel_authors":[{"author_name":"Bob Boogaard","author_inst":"Erasmus MC"},{"author_name":"Joep Nijssen","author_inst":"Delft University of Technology"},{"author_name":"Freek Broeren","author_inst":"Delft University of Technology"},{"author_name":"John van den Dobbelsteen","author_inst":"Delft University of Technology"},{"author_name":"Vincent Verhoeven","author_inst":"Reinier de Graaf Gasthuis"},{"author_name":"Jip Pluim","author_inst":"Reinier de Graaf Gasthuis"},{"author_name":"Sing Dekker","author_inst":"Reinier de Graaf Gasthuis"},{"author_name":"Eric Snijder","author_inst":"Leiden University Medical Center (LUMC)"},{"author_name":"Martijn van Hemert","author_inst":"Leiden University Medical Center (LUMC)"},{"author_name":"Sander Herfst","author_inst":"Erasmus MC"},{"author_name":"Hong Chen","author_inst":"Center of Integrative Research, The First Hospital of Qiqihar City, Qiqihar, Heilongjiang 161005, P.R. China."},{"author_name":"Julia Laviano","author_inst":"Instituto Universitario CEMIC"},{"author_name":"Daniela Maymo","author_inst":"Instituto Universitario CEMIC"},{"author_name":"Daniel Gotta","author_inst":"Centro de Educacion Medica e Investigaciones Clinicas (CEMIC)"},{"author_name":"Alfredo Martinez","author_inst":"Centro de Educacion Medica e Investigaciones Clinicas (CEMIC)"},{"author_name":"Pablo Bonvehi","author_inst":"Centro de Educacion Medica e Investigaciones Clinicas (CEMIC)"},{"author_name":"Arianne Plaschke","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"David Eisel","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Sarah Dany","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Stephanie Fesser","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Stephanie Erbar","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"ferdia Bates","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Diana Schneider","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Bernadette Jesionek","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Bianca Saenger","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Ann-Kathrin Wallisch","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Yvonne Feuchter","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Hanna Junginger","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Stefanie Krumm","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Andre Heinen","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Petra Adams-Quack","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Julia Schlereth","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Christoph Kroener","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Shannan Hall-Ursone","author_inst":"University of Texas Medical Branch"},{"author_name":"Kathleen Brasky","author_inst":"University of Texas Medical Branch"},{"author_name":"Matthew C Griffor","author_inst":"Pfizer Inc."},{"author_name":"Seungil Han","author_inst":"Pfizer Inc"},{"author_name":"Joshua Lees","author_inst":"Pfizer Inc."},{"author_name":"Ellene Mashalidis","author_inst":"Pfizer Inc."},{"author_name":"Parag Sahasrabudhe","author_inst":"Pfizer Inc."},{"author_name":"Charles Tan","author_inst":"Pfizer Inc."},{"author_name":"Danka Pavliakova","author_inst":"Pfizer Inc."},{"author_name":"Guy Singh","author_inst":"Pfizer Inc."},{"author_name":"Camila Fontes-Garfias","author_inst":"University of Texas Medical Branch"},{"author_name":"Michael Pride","author_inst":"Pfizer Inc."},{"author_name":"Ingrid Scully","author_inst":"Pfizer Inc."},{"author_name":"tara Ciolino","author_inst":"Pfizer Inc."},{"author_name":"Jennifer Obregon","author_inst":"Pfizer Inc."},{"author_name":"Michal Gazi","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Ricardo Carrion","author_inst":"University of Texas Medical Branch"},{"author_name":"Kendra Alfson","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Warren Kalina","author_inst":"Pfizer Inc."},{"author_name":"Deepak Kaushal","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Thorsten Klamp","author_inst":"BioNTech SE"},{"author_name":"Corinna Rosenbaum","author_inst":"BioNTech SE"},{"author_name":"Andreas Kuhn","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech SE"},{"author_name":"Philip Dormitzer","author_inst":"Pfizer Inc."},{"author_name":"Kathrin Jansen","author_inst":"Pfizer Inc."},{"author_name":"Ugur Sahin","author_inst":"BioNTech SE"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"occupational and environmental health"},{"rel_doi":"10.1101\/2020.09.02.20185892","rel_title":"Prognostic accuracy of emergency department triage tools for adults with suspected COVID-19: The PRIEST observational cohort study","rel_date":"2020-09-07","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.09.02.20185892","rel_abs":"Objectives: The World Health Organisation (WHO) and National Institute for Health and Care Excellence (NICE) recommend various triage tools to assist decision-making for patients with suspected COVID-19. We aimed to estimate the accuracy of triage tools for predicting severe illness in adults presenting to the emergency department (ED) with suspected COVID-19 infection. Methods: We undertook a mixed prospective and retrospective observational cohort study in 70 EDs across the United Kingdom (UK). We collected data from people attending with suspected COVID-19 between 26 March 2020 and 28 May 2020, and used presenting data to determine the results of assessment with the following triage tools: the WHO algorithm, NEWS2, CURB-65, CRB-65, PMEWS and the swine flu adult hospital pathway (SFAHP). We used 30-day outcome data (death or receipt of respiratory, cardiovascular or renal support) to determine prognostic accuracy for adverse outcome. Results: We analysed data from 20892 adults, of whom 4672 (22.4%) died or received organ support (primary outcome), with 2058 (9.9%) receiving organ support and 2614 (12.5%) dying without organ support (secondary outcomes). C-statistics for the primary outcome were: CURB-65 0.75; CRB-65 0.70; PMEWS 0.77; NEWS2 (score) 0.77; NEWS2 (rule) 0.69; SFAHP (6-point) 0.70; SFAHP (7-point) 0.68; WHO algorithm 0.61. All triage tools showed worse prediction for receipt of organ support and better prediction for death without organ support. At the recommended threshold, PMEWS and the WHO criteria showed good sensitivity (0.96 and 0.95 respectively), at the expense of specificity (0.31 and 0.27 respectively). NEWS2 showed similar sensitivity (0.96) and specificity (0.28) when a lower threshold than recommended was used. Conclusion: CURB-65, PMEWS and NEWS2 provide good but not excellent prediction for adverse outcome in suspected COVID-19, and predicted death without organ support better than receipt of organ support. PMEWS, the WHO criteria and NEWS2 (using a lower threshold than usually recommended) provide good sensitivity at the expense of specificity.","rel_num_authors":22,"rel_authors":[{"author_name":"Ben Thomas","author_inst":"University of Sheffield"},{"author_name":"Steve Goodacre","author_inst":"University of Sheffield"},{"author_name":"Ellen Lee","author_inst":"University of Sheffield"},{"author_name":"Laura Sutton","author_inst":"University of Sheffield"},{"author_name":"Amanda Loban","author_inst":"University of Sheffield"},{"author_name":"Simon Waterhouse","author_inst":"University of Sheffield"},{"author_name":"Richard Simmonds","author_inst":"University of Sheffield"},{"author_name":"Katie Biggs","author_inst":"University of Sheffield"},{"author_name":"Carl Marincowitz","author_inst":"University of Sheffield"},{"author_name":"Jose Schutter","author_inst":"University of Sheffield"},{"author_name":"Sarah Connelly","author_inst":"University of Sheffield"},{"author_name":"Elena Sheldon","author_inst":"University of Sheffield"},{"author_name":"Jamie Hall","author_inst":"University of Sheffield"},{"author_name":"Emma Young","author_inst":"University of Sheffield"},{"author_name":"Andrew Bentley","author_inst":"Manchester University NHS Foundation Trust"},{"author_name":"Kirsty Challen","author_inst":"Lancashire Teaching Hospitals NHS Foundation Trust"},{"author_name":"Chris Fitzsimmons","author_inst":"Sheffield Children's NHS Foundation Trust"},{"author_name":"Tim Harris","author_inst":"Barts Health NHS Trust"},{"author_name":"Fiona Lecky","author_inst":"University of Sheffield"},{"author_name":"Andrew Lee","author_inst":"University of Sheffield"},{"author_name":"Ian Maconochie","author_inst":"Imperial College Healthcare NHS Trust"},{"author_name":"Darren Walter","author_inst":"Manchester University NHS Foundation Trust"},{"author_name":"Diana Schneider","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Bernadette Jesionek","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Bianca Saenger","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Ann-Kathrin Wallisch","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Yvonne Feuchter","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Hanna Junginger","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Stefanie Krumm","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Andre Heinen","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Petra Adams-Quack","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Julia Schlereth","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Christoph Kroener","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Shannan Hall-Ursone","author_inst":"University of Texas Medical Branch"},{"author_name":"Kathleen Brasky","author_inst":"University of Texas Medical Branch"},{"author_name":"Matthew C Griffor","author_inst":"Pfizer Inc."},{"author_name":"Seungil Han","author_inst":"Pfizer Inc"},{"author_name":"Joshua Lees","author_inst":"Pfizer Inc."},{"author_name":"Ellene Mashalidis","author_inst":"Pfizer Inc."},{"author_name":"Parag Sahasrabudhe","author_inst":"Pfizer Inc."},{"author_name":"Charles Tan","author_inst":"Pfizer Inc."},{"author_name":"Danka Pavliakova","author_inst":"Pfizer Inc."},{"author_name":"Guy Singh","author_inst":"Pfizer Inc."},{"author_name":"Camila Fontes-Garfias","author_inst":"University of Texas Medical Branch"},{"author_name":"Michael Pride","author_inst":"Pfizer Inc."},{"author_name":"Ingrid Scully","author_inst":"Pfizer Inc."},{"author_name":"tara Ciolino","author_inst":"Pfizer Inc."},{"author_name":"Jennifer Obregon","author_inst":"Pfizer Inc."},{"author_name":"Michal Gazi","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Ricardo Carrion","author_inst":"University of Texas Medical Branch"},{"author_name":"Kendra Alfson","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Warren Kalina","author_inst":"Pfizer Inc."},{"author_name":"Deepak Kaushal","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Thorsten Klamp","author_inst":"BioNTech SE"},{"author_name":"Corinna Rosenbaum","author_inst":"BioNTech SE"},{"author_name":"Andreas Kuhn","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech SE"},{"author_name":"Philip Dormitzer","author_inst":"Pfizer Inc."},{"author_name":"Kathrin Jansen","author_inst":"Pfizer Inc."},{"author_name":"Ugur Sahin","author_inst":"BioNTech SE"}],"version":"1","license":"cc_by","type":"PUBLISHAHEADOFPRINT","category":"emergency medicine"},{"rel_doi":"10.1101\/2020.09.04.20185645","rel_title":"Predicting illness trajectory and hospital resource utilization of COVID-19 hospitalized patients - a nationwide study","rel_date":"2020-09-07","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.09.04.20185645","rel_abs":"Importance: The spread of COVID-19 has led to a severe strain on hospital capacity in many countries. There is a need for a model to help planners assess expected COVID-19 hospital resource utilization. Objective: Provide publicly available tools for predicting future hospital-bed utilization given a succinct characterization of the status of currently hospitalized patients and scenarios for future incoming patients. Design: Retrospective cohort study following the day-by-day clinical status of all hospitalized COVID-19 patients in Israel from March 1st to May 2nd, 2020. Patient clinical course was modelled with a machine learning approach based on a set of multistate Cox regression-based models with adjustments for right censoring, recurrent events, competing events, left truncation, and time-dependent covariates. The model predicts the patient's entire disease course in terms of clinical states, from which we derive the patient's hospital length-of-stay, length-of-stay in critical state, risk of in-hospital mortality, and overall hospital-bed utilization. Accuracy assessed over 8 cross-validation cohorts of size 330, using per-day Mean Absolute Error (MAE) of predicted hospital utilization over time; and area under the receiver operating characteristics (AUROC) for individual risk of critical illness and in-hospital mortality, assessed on the first day of hospitalization. We present predicted hospital utilization under hypothetical incoming patient scenarios. Setting: 27 Israeli hospitals. Participants: During the study period, 2,703 confirmed COVID-19 patients were hospitalized in Israel for 1 day or more; 28 were excluded due to missing age or sex; the remaining 2,675 patients were included in the analysis. Main Outcomes and Measures: Primary outcome: per-day estimate of total number of hospitalized patients and number of patients in critical state; secondary outcome: risk of a single patient experiencing critical illness or in-hospital mortality. Results: For random validation samples of 330 patients, the per-day MAEs for total hospital-bed utilization and critical-bed utilization, averaged over 64 days, were 4.72 {+\/-} 1.07 and $1.68 {+\/-} 0.40 respectively; the AUROCs for prediction of the probabilities of critical illness and in-hospital mortality were 0.88 {+\/-} 0.04 and 0.96 {+\/-} 0.04, respectively. We further present the impact of several scenarios of patient influx on healthcare system utilization, demonstrating the ability to accurately plan ahead how to allocate healthcare resources. Conclusions and Relevance: We developed a model that, given basic easily obtained data as input, accurately predicts total and critical care hospital utilization. The model enables evaluating the impact of various patient influx scenarios on hospital utilization. Accurate predictions are also given for individual patients' probability of in-hospital mortality and critical illness. We further provide an R software package and a web-application for the model.","rel_num_authors":12,"rel_authors":[{"author_name":"Michael Roimi","author_inst":"Rambam Health Care Campus"},{"author_name":"Rom Gutman","author_inst":"Technion - Israel Institute of Technology"},{"author_name":"Jonathan Somer","author_inst":"Technion - Israel Institute of Technology"},{"author_name":"Asaf Ben Arie","author_inst":"Tel Aviv University"},{"author_name":"Ido Calman","author_inst":"Independent"},{"author_name":"Yaron Bar-Lavie","author_inst":"Rambam Health Care Campus"},{"author_name":"Udi Gelbshtein","author_inst":"Israel Ministry of Health"},{"author_name":"Sigal Liverant-Taub","author_inst":"Israel Ministry of Health"},{"author_name":"Arnona Ziv","author_inst":"Gertner Institute for Epidemiology and Health Policy Research"},{"author_name":"Danny Eytan","author_inst":"Technion - Israel Institute of Technology and Rambam Health Care Campus"},{"author_name":"Malka Gorfine","author_inst":"Tel Aviv University"},{"author_name":"Uri Shalit","author_inst":"Technion - Israeli Institute of Technology"},{"author_name":"Jamie Hall","author_inst":"University of Sheffield"},{"author_name":"Emma Young","author_inst":"University of Sheffield"},{"author_name":"Andrew Bentley","author_inst":"Manchester University NHS Foundation Trust"},{"author_name":"Kirsty Challen","author_inst":"Lancashire Teaching Hospitals NHS Foundation Trust"},{"author_name":"Chris Fitzsimmons","author_inst":"Sheffield Children's NHS Foundation Trust"},{"author_name":"Tim Harris","author_inst":"Barts Health NHS Trust"},{"author_name":"Fiona Lecky","author_inst":"University of Sheffield"},{"author_name":"Andrew Lee","author_inst":"University of Sheffield"},{"author_name":"Ian Maconochie","author_inst":"Imperial College Healthcare NHS Trust"},{"author_name":"Darren Walter","author_inst":"Manchester University NHS Foundation Trust"},{"author_name":"Diana Schneider","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Bernadette Jesionek","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Bianca Saenger","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Ann-Kathrin Wallisch","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Yvonne Feuchter","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Hanna Junginger","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Stefanie Krumm","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Andre Heinen","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Petra Adams-Quack","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Julia Schlereth","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Christoph Kroener","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Shannan Hall-Ursone","author_inst":"University of Texas Medical Branch"},{"author_name":"Kathleen Brasky","author_inst":"University of Texas Medical Branch"},{"author_name":"Matthew C Griffor","author_inst":"Pfizer Inc."},{"author_name":"Seungil Han","author_inst":"Pfizer Inc"},{"author_name":"Joshua Lees","author_inst":"Pfizer Inc."},{"author_name":"Ellene Mashalidis","author_inst":"Pfizer Inc."},{"author_name":"Parag Sahasrabudhe","author_inst":"Pfizer Inc."},{"author_name":"Charles Tan","author_inst":"Pfizer Inc."},{"author_name":"Danka Pavliakova","author_inst":"Pfizer Inc."},{"author_name":"Guy Singh","author_inst":"Pfizer Inc."},{"author_name":"Camila Fontes-Garfias","author_inst":"University of Texas Medical Branch"},{"author_name":"Michael Pride","author_inst":"Pfizer Inc."},{"author_name":"Ingrid Scully","author_inst":"Pfizer Inc."},{"author_name":"tara Ciolino","author_inst":"Pfizer Inc."},{"author_name":"Jennifer Obregon","author_inst":"Pfizer Inc."},{"author_name":"Michal Gazi","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Ricardo Carrion","author_inst":"University of Texas Medical Branch"},{"author_name":"Kendra Alfson","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Warren Kalina","author_inst":"Pfizer Inc."},{"author_name":"Deepak Kaushal","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Thorsten Klamp","author_inst":"BioNTech SE"},{"author_name":"Corinna Rosenbaum","author_inst":"BioNTech SE"},{"author_name":"Andreas Kuhn","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech SE"},{"author_name":"Philip Dormitzer","author_inst":"Pfizer Inc."},{"author_name":"Kathrin Jansen","author_inst":"Pfizer Inc."},{"author_name":"Ugur Sahin","author_inst":"BioNTech SE"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"health policy"},{"rel_doi":"10.1101\/2020.09.04.20184523","rel_title":"MOLECULAR EPIDEMIOLOGY TO UNDERSTAND THE SARS-CoV-2 EMERGENCE IN THE BRAZILIAN AMAZON REGION","rel_date":"2020-09-07","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.09.04.20184523","rel_abs":"The COVID-19 pandemic in Brazil has demonstrated an important public health impact, as has been observed in the world. In Brazil, the Amazon Region contributed with a large number of cases of COVID-19, especially in the beginning of the circulation of SARS-CoV-2 in the country. Thus, we describe the epidemiological profile of COVID-19 and the genetic diversity of SARS-CoV-2 strains circulating in the Amazon Region. We observe an extensive spread of virus in this Brazilian site. The data on sex, age and symptoms presented by the investigated individuals were similar to what has been observed worldwide. The genomic analysis of the viruses revealed important amino acid changes, including the D614G and the I33T in Spike and ORF6 proteins, respectively. The latter found in strains originating in Brazil. The phylogenetic analyzes demonstrated the circulation of the lineages B.1 and B.1.1, whose circulation in Brazil has already been previous reported. Our data reveals molecular epidemiology of SARS-CoV-2 in the Amazon Region. These findings also reinforce the importance of continuous genomic surveillance this virus with the aim of providing accurate and updated data to understand and map the transmission network of this agent in order to subsidize operational decisions in public health.","rel_num_authors":44,"rel_authors":[{"author_name":"Mirleide C dos Santos","author_inst":"Instituto Evandro Chagas"},{"author_name":"Edivaldo Costa Sousa Jr.","author_inst":"Instituto Evandro Chagas"},{"author_name":"Jessylene A Ferreira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Sandro P Silva","author_inst":"Instituto Evandro Chagas"},{"author_name":"Michel PC Souza","author_inst":"Instituto Evandro Chagas"},{"author_name":"Jedson F Cardoso","author_inst":"Instituto Evandro Chagas"},{"author_name":"Amanda M Silva","author_inst":"Instituto Evandro Chagas"},{"author_name":"Luana S Barbagelata","author_inst":"Instituto Evandro Chagas"},{"author_name":"Wanderley D Chagas Jr.","author_inst":"Instituto Evandro Chagas"},{"author_name":"James L Ferreira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Edna MA Souza","author_inst":"Instituto Evandro Chagas"},{"author_name":"Patricia LA Vilaca","author_inst":"Instituto Evandro Chagas"},{"author_name":"Jainara CS Alves","author_inst":"Instituto Evandro Chagas"},{"author_name":"Michelle C Abreu","author_inst":"Instituto Evandro Chagas"},{"author_name":"Patricia S Lobo","author_inst":"Instituto Evandro Chagas"},{"author_name":"Fabiolla S Santos","author_inst":"Instituto Evandro Chagas"},{"author_name":"Alessandra AP Lima","author_inst":"Instituto Evandro Chagas"},{"author_name":"Camila M Bragagnolo","author_inst":"Instituto Evandro Chagas"},{"author_name":"Luana S Soares","author_inst":"Instituto Evandro Chagas"},{"author_name":"Patricia SM Almeida","author_inst":"Instituto Evandro Chagas"},{"author_name":"Darleise S Oliveira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Carolina KN Amorim","author_inst":"Instituto Evandro Chagas"},{"author_name":"Iran B Costa","author_inst":"Instituto Evandro Chagas"},{"author_name":"Dielle M Teixeira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Edvaldo T Penha Jr.","author_inst":"Instituto Evandro Chagas"},{"author_name":"Delana AM Bezerra","author_inst":"Instituto Evandro Chagas"},{"author_name":"Jones AM Siqueira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Fernando N Tavares","author_inst":"Instituto Evandro Chagas"},{"author_name":"Felipe B Freitas","author_inst":"Instituto Evandro Chagas"},{"author_name":"Janete TN Rodrigues","author_inst":"Laboratorio Central de Saude Publica do Acre"},{"author_name":"Janaina Mazaro","author_inst":"Laboratorio Central de Saude Publica do Acre"},{"author_name":"Andreia S Costa","author_inst":"Laboratorio Central de Saude Publica do Amapa"},{"author_name":"Marcia SP Cavalcante","author_inst":"Laboratorio Central de Saude Publica do Amapa"},{"author_name":"Marineide Souza Silva","author_inst":"Laboratorio Central de Saude Publica do Amazonas"},{"author_name":"Ilvanete A Silva","author_inst":"Laboratorio Central de Saude Publica do Para"},{"author_name":"Gleissy AL Borges","author_inst":"Laboratorio Central de Saude Publica do Para"},{"author_name":"Lidio G Lima","author_inst":"Laboratorio Central de Saude Publica do Maranhao"},{"author_name":"Hivylla LS Ferreira","author_inst":"Laboratorio Central de Saude Publica do Maranhao"},{"author_name":"Miriam TFP Livorati","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Andre L Abreu","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Arnaldo C Medeiros","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Hugo R Resque","author_inst":"Instituto Evandro Chagas"},{"author_name":"Rita CM Sousa","author_inst":"Programa de Pos Graduacao em Virologia - Instituto Evandro Chagas"},{"author_name":"Giselle MR Viana","author_inst":"Instituto Evandro Chagas"},{"author_name":"Michael Pride","author_inst":"Pfizer Inc."},{"author_name":"Ingrid Scully","author_inst":"Pfizer Inc."},{"author_name":"tara Ciolino","author_inst":"Pfizer Inc."},{"author_name":"Jennifer Obregon","author_inst":"Pfizer Inc."},{"author_name":"Michal Gazi","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Ricardo Carrion","author_inst":"University of Texas Medical Branch"},{"author_name":"Kendra Alfson","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Warren Kalina","author_inst":"Pfizer Inc."},{"author_name":"Deepak Kaushal","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Thorsten Klamp","author_inst":"BioNTech SE"},{"author_name":"Corinna Rosenbaum","author_inst":"BioNTech SE"},{"author_name":"Andreas Kuhn","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech SE"},{"author_name":"Philip Dormitzer","author_inst":"Pfizer Inc."},{"author_name":"Kathrin Jansen","author_inst":"Pfizer Inc."},{"author_name":"Ugur Sahin","author_inst":"BioNTech SE"}],"version":"1","license":"cc_by_nd","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.09.04.20184721","rel_title":"Emergence of the D614A mutation in the spike protein of SARS-CoV-2: Imported cases to the South Korea","rel_date":"2020-09-07","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.09.04.20184721","rel_abs":"We identified imported cases of a novel D614A mutation in the spike glycoprotein of SARS-CoV-2 in the South Korea. SARS-CoV-2 harboring the novel mutation was isolated from returning travelers from Uzbekistan. These results emphasized the possibility that new mutations have emerged in that area.","rel_num_authors":14,"rel_authors":[{"author_name":"Ae Kyung Park","author_inst":"Korea Centers for Disease Control & Prevention"},{"author_name":"Jin Sun No","author_inst":"Korea Centers for Disease Control & Prevention"},{"author_name":"Eunkyung Shin","author_inst":"Korea Centers for Diseases Control and Prevention"},{"author_name":"Yoon-Seok Chung","author_inst":"Korea Centers for Disease Control & Prevention"},{"author_name":"Il-Hwan Kim","author_inst":"Korea Centers for Disease Control & Prevention"},{"author_name":"Byung-Hak Kang","author_inst":"Korea Centers for Disease Control & Prevention"},{"author_name":"Gi-Eun Rhie","author_inst":"Korea Centers for Disease Control & Prevention"},{"author_name":"Heui Man Kim","author_inst":"Korea Centers for Disease Control & Prevention"},{"author_name":"Jeong-Min Kim","author_inst":"Korea Centers for Disease Control & Prevention"},{"author_name":"Ye Eun Park","author_inst":"Korea Centers for Disease Control & Prevention"},{"author_name":"Min Joon Kim","author_inst":"Korea Centers for Disease Control & Prevention"},{"author_name":"Jae Sun Park","author_inst":"Korea Centers for Disease Control & Prevention"},{"author_name":"Cheon-Kwon Yoo","author_inst":"Korea Centers for Disease Control & Prevention"},{"author_name":"Junyoung Kim","author_inst":"Korea Centers for Diseases Control and Prevention"},{"author_name":"Patricia S Lobo","author_inst":"Instituto Evandro Chagas"},{"author_name":"Fabiolla S Santos","author_inst":"Instituto Evandro Chagas"},{"author_name":"Alessandra AP Lima","author_inst":"Instituto Evandro Chagas"},{"author_name":"Camila M Bragagnolo","author_inst":"Instituto Evandro Chagas"},{"author_name":"Luana S Soares","author_inst":"Instituto Evandro Chagas"},{"author_name":"Patricia SM Almeida","author_inst":"Instituto Evandro Chagas"},{"author_name":"Darleise S Oliveira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Carolina KN Amorim","author_inst":"Instituto Evandro Chagas"},{"author_name":"Iran B Costa","author_inst":"Instituto Evandro Chagas"},{"author_name":"Dielle M Teixeira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Edvaldo T Penha Jr.","author_inst":"Instituto Evandro Chagas"},{"author_name":"Delana AM Bezerra","author_inst":"Instituto Evandro Chagas"},{"author_name":"Jones AM Siqueira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Fernando N Tavares","author_inst":"Instituto Evandro Chagas"},{"author_name":"Felipe B Freitas","author_inst":"Instituto Evandro Chagas"},{"author_name":"Janete TN Rodrigues","author_inst":"Laboratorio Central de Saude Publica do Acre"},{"author_name":"Janaina Mazaro","author_inst":"Laboratorio Central de Saude Publica do Acre"},{"author_name":"Andreia S Costa","author_inst":"Laboratorio Central de Saude Publica do Amapa"},{"author_name":"Marcia SP Cavalcante","author_inst":"Laboratorio Central de Saude Publica do Amapa"},{"author_name":"Marineide Souza Silva","author_inst":"Laboratorio Central de Saude Publica do Amazonas"},{"author_name":"Ilvanete A Silva","author_inst":"Laboratorio Central de Saude Publica do Para"},{"author_name":"Gleissy AL Borges","author_inst":"Laboratorio Central de Saude Publica do Para"},{"author_name":"Lidio G Lima","author_inst":"Laboratorio Central de Saude Publica do Maranhao"},{"author_name":"Hivylla LS Ferreira","author_inst":"Laboratorio Central de Saude Publica do Maranhao"},{"author_name":"Miriam TFP Livorati","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Andre L Abreu","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Arnaldo C Medeiros","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Hugo R Resque","author_inst":"Instituto Evandro Chagas"},{"author_name":"Rita CM Sousa","author_inst":"Programa de Pos Graduacao em Virologia - Instituto Evandro Chagas"},{"author_name":"Giselle MR Viana","author_inst":"Instituto Evandro Chagas"},{"author_name":"Michael Pride","author_inst":"Pfizer Inc."},{"author_name":"Ingrid Scully","author_inst":"Pfizer Inc."},{"author_name":"tara Ciolino","author_inst":"Pfizer Inc."},{"author_name":"Jennifer Obregon","author_inst":"Pfizer Inc."},{"author_name":"Michal Gazi","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Ricardo Carrion","author_inst":"University of Texas Medical Branch"},{"author_name":"Kendra Alfson","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Warren Kalina","author_inst":"Pfizer Inc."},{"author_name":"Deepak Kaushal","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Thorsten Klamp","author_inst":"BioNTech SE"},{"author_name":"Corinna Rosenbaum","author_inst":"BioNTech SE"},{"author_name":"Andreas Kuhn","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech SE"},{"author_name":"Philip Dormitzer","author_inst":"Pfizer Inc."},{"author_name":"Kathrin Jansen","author_inst":"Pfizer Inc."},{"author_name":"Ugur Sahin","author_inst":"BioNTech SE"}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.09.04.20188631","rel_title":"Contact tracing efficiency, transmission heterogeneity, and accelerating COVID-19 epidemics","rel_date":"2020-09-07","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.09.04.20188631","rel_abs":"Simultaneously controlling COVID-19 epidemics and limiting economic and societal impacts presents a difficult challenge, especially with limited public health budgets. Testing, contact tracing, and isolating\/quarantining is a key strategy that has been used to reduce transmission of SARS-CoV-2, the virus that causes COVID-19. However, manual contact tracing is a time-consuming process and as case numbers increase it takes longer to reach each cases' contacts, leading to additional virus spread. Delays between symptom onset and being tested (and receiving results), and a low fraction of symptomatic cases being tested and traced can also reduce the impact of contact tracing on transmission. We examined the relationship between cases and delays and the pathogen reproductive number Rt, and the implications for infection dynamics using a stochastic compartment model of SARS-CoV-2. We found that Rt increases sigmoidally with the number of cases due to decreasing contact tracing efficacy. This relationship results in accelerating epidemics because Rt increases, rather than declines, as infections increase. Shifting contact tracers from locations with high and low case burdens relative to capacity to locations with intermediate case burdens maximizes their impact in reducing Rt (but minimizing total infections is more complicated). Contact tracing efficacy also decreased with increasing delays between symptom onset and tracing and with lower fraction of symptomatic infections being tested. Finally, testing and tracing reductions in Rt can sometimes greatly delay epidemics due to the highly heterogeneous transmission dynamics of SARS-CoV-2. These results demonstrate the importance of having an expandable or mobile team of contact tracers that can be used to control surges in cases, and the value of easy access, high testing capacity and rapid turn-around of testing results, as well as outreach efforts to encourage symptomatic infections to be tested immediately after symptom onset.","rel_num_authors":2,"rel_authors":[{"author_name":"Billy J Gardner","author_inst":"University of California, Santa Cruz"},{"author_name":"A. Marm Kilpatrick","author_inst":"University of California, Santa Cruz"},{"author_name":"Eunkyung Shin","author_inst":"Korea Centers for Diseases Control and Prevention"},{"author_name":"Yoon-Seok Chung","author_inst":"Korea Centers for Disease Control & Prevention"},{"author_name":"Il-Hwan Kim","author_inst":"Korea Centers for Disease Control & Prevention"},{"author_name":"Byung-Hak Kang","author_inst":"Korea Centers for Disease Control & Prevention"},{"author_name":"Gi-Eun Rhie","author_inst":"Korea Centers for Disease Control & Prevention"},{"author_name":"Heui Man Kim","author_inst":"Korea Centers for Disease Control & Prevention"},{"author_name":"Jeong-Min Kim","author_inst":"Korea Centers for Disease Control & Prevention"},{"author_name":"Ye Eun Park","author_inst":"Korea Centers for Disease Control & Prevention"},{"author_name":"Min Joon Kim","author_inst":"Korea Centers for Disease Control & Prevention"},{"author_name":"Jae Sun Park","author_inst":"Korea Centers for Disease Control & Prevention"},{"author_name":"Cheon-Kwon Yoo","author_inst":"Korea Centers for Disease Control & Prevention"},{"author_name":"Junyoung Kim","author_inst":"Korea Centers for Diseases Control and Prevention"},{"author_name":"Patricia S Lobo","author_inst":"Instituto Evandro Chagas"},{"author_name":"Fabiolla S Santos","author_inst":"Instituto Evandro Chagas"},{"author_name":"Alessandra AP Lima","author_inst":"Instituto Evandro Chagas"},{"author_name":"Camila M Bragagnolo","author_inst":"Instituto Evandro Chagas"},{"author_name":"Luana S Soares","author_inst":"Instituto Evandro Chagas"},{"author_name":"Patricia SM Almeida","author_inst":"Instituto Evandro Chagas"},{"author_name":"Darleise S Oliveira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Carolina KN Amorim","author_inst":"Instituto Evandro Chagas"},{"author_name":"Iran B Costa","author_inst":"Instituto Evandro Chagas"},{"author_name":"Dielle M Teixeira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Edvaldo T Penha Jr.","author_inst":"Instituto Evandro Chagas"},{"author_name":"Delana AM Bezerra","author_inst":"Instituto Evandro Chagas"},{"author_name":"Jones AM Siqueira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Fernando N Tavares","author_inst":"Instituto Evandro Chagas"},{"author_name":"Felipe B Freitas","author_inst":"Instituto Evandro Chagas"},{"author_name":"Janete TN Rodrigues","author_inst":"Laboratorio Central de Saude Publica do Acre"},{"author_name":"Janaina Mazaro","author_inst":"Laboratorio Central de Saude Publica do Acre"},{"author_name":"Andreia S Costa","author_inst":"Laboratorio Central de Saude Publica do Amapa"},{"author_name":"Marcia SP Cavalcante","author_inst":"Laboratorio Central de Saude Publica do Amapa"},{"author_name":"Marineide Souza Silva","author_inst":"Laboratorio Central de Saude Publica do Amazonas"},{"author_name":"Ilvanete A Silva","author_inst":"Laboratorio Central de Saude Publica do Para"},{"author_name":"Gleissy AL Borges","author_inst":"Laboratorio Central de Saude Publica do Para"},{"author_name":"Lidio G Lima","author_inst":"Laboratorio Central de Saude Publica do Maranhao"},{"author_name":"Hivylla LS Ferreira","author_inst":"Laboratorio Central de Saude Publica do Maranhao"},{"author_name":"Miriam TFP Livorati","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Andre L Abreu","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Arnaldo C Medeiros","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Hugo R Resque","author_inst":"Instituto Evandro Chagas"},{"author_name":"Rita CM Sousa","author_inst":"Programa de Pos Graduacao em Virologia - Instituto Evandro Chagas"},{"author_name":"Giselle MR Viana","author_inst":"Instituto Evandro Chagas"},{"author_name":"Michael Pride","author_inst":"Pfizer Inc."},{"author_name":"Ingrid Scully","author_inst":"Pfizer Inc."},{"author_name":"tara Ciolino","author_inst":"Pfizer Inc."},{"author_name":"Jennifer Obregon","author_inst":"Pfizer Inc."},{"author_name":"Michal Gazi","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Ricardo Carrion","author_inst":"University of Texas Medical Branch"},{"author_name":"Kendra Alfson","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Warren Kalina","author_inst":"Pfizer Inc."},{"author_name":"Deepak Kaushal","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Thorsten Klamp","author_inst":"BioNTech SE"},{"author_name":"Corinna Rosenbaum","author_inst":"BioNTech SE"},{"author_name":"Andreas Kuhn","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech SE"},{"author_name":"Philip Dormitzer","author_inst":"Pfizer Inc."},{"author_name":"Kathrin Jansen","author_inst":"Pfizer Inc."},{"author_name":"Ugur Sahin","author_inst":"BioNTech SE"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.09.04.20188318","rel_title":"Trans-ethnic analysis reveals genetic and non-genetic associations with COVID-19 susceptibility and severity","rel_date":"2020-09-07","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.09.04.20188318","rel_abs":"COVID-19 presents with a wide range of severity, from asymptomatic in some individuals to fatal in others. Based on a study of over one million 23andMe research participants, we report genetic and non-genetic associations with testing positive for COVID-19, respiratory symptoms, and hospitalization. Risk factors for hospitalization include advancing age, male sex, elevated body mass index, lower socio-economic status, non-European ancestry, and pre-existing cardio-metabolic and respiratory conditions. Using trans-ethnic genome-wide association studies, we identify a strong association between blood type and COVID-19 diagnosis, as well as a gene-rich locus on chr3p21.31 that is more strongly associated with outcome severity. While non-European ancestry was found to be a significant risk factor for hospitalization after adjusting for socio-demographics and pre-existing health conditions, we did not find evidence that these two primary genetic associations explain differences between populations in terms of risk for severe COVID-19 outcomes.","rel_num_authors":11,"rel_authors":[{"author_name":"Janie F. Shelton","author_inst":"23andMe Inc., 223 N Mathilda Ave, Sunnyvale, CA 94086"},{"author_name":"Anjali J. Shastri","author_inst":"23andMe Inc., 223 N Mathilda Ave, Sunnyvale, CA 94086"},{"author_name":"Chelsea Ye","author_inst":"23andMe Inc., 223 N Mathilda Ave, Sunnyvale, CA 94086"},{"author_name":"Catherine H. Weldon","author_inst":"23andMe Inc., 223 N Mathilda Ave, Sunnyvale, CA 94086"},{"author_name":"Teresa Filshtein-Somnez","author_inst":"23andMe Inc., 223 N Mathilda Ave, Sunnyvale, CA 94086"},{"author_name":"Daniella Coker","author_inst":"23andMe Inc., 223 N Mathilda Ave, Sunnyvale, CA 94086"},{"author_name":"Antony Symons","author_inst":"23andMe Inc., 223 N Mathilda Ave, Sunnyvale, CA 94086"},{"author_name":"Jorge Esparza-Gordillo","author_inst":"Human genetics - R&D, GSK Medicines Research Centre, Target Sciences-R&D, Stevenage, UK"},{"author_name":"- The 23andMe COVID-19 Team","author_inst":""},{"author_name":"Stella Aslibekyan","author_inst":"23andMe Inc., 223 N Mathilda Ave, Sunnyvale, CA 94086"},{"author_name":"Adam Auton","author_inst":"23andMe Inc., 223 N Mathilda Ave, Sunnyvale, CA 94086"},{"author_name":"Jae Sun Park","author_inst":"Korea Centers for Disease Control & Prevention"},{"author_name":"Cheon-Kwon Yoo","author_inst":"Korea Centers for Disease Control & Prevention"},{"author_name":"Junyoung Kim","author_inst":"Korea Centers for Diseases Control and Prevention"},{"author_name":"Patricia S Lobo","author_inst":"Instituto Evandro Chagas"},{"author_name":"Fabiolla S Santos","author_inst":"Instituto Evandro Chagas"},{"author_name":"Alessandra AP Lima","author_inst":"Instituto Evandro Chagas"},{"author_name":"Camila M Bragagnolo","author_inst":"Instituto Evandro Chagas"},{"author_name":"Luana S Soares","author_inst":"Instituto Evandro Chagas"},{"author_name":"Patricia SM Almeida","author_inst":"Instituto Evandro Chagas"},{"author_name":"Darleise S Oliveira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Carolina KN Amorim","author_inst":"Instituto Evandro Chagas"},{"author_name":"Iran B Costa","author_inst":"Instituto Evandro Chagas"},{"author_name":"Dielle M Teixeira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Edvaldo T Penha Jr.","author_inst":"Instituto Evandro Chagas"},{"author_name":"Delana AM Bezerra","author_inst":"Instituto Evandro Chagas"},{"author_name":"Jones AM Siqueira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Fernando N Tavares","author_inst":"Instituto Evandro Chagas"},{"author_name":"Felipe B Freitas","author_inst":"Instituto Evandro Chagas"},{"author_name":"Janete TN Rodrigues","author_inst":"Laboratorio Central de Saude Publica do Acre"},{"author_name":"Janaina Mazaro","author_inst":"Laboratorio Central de Saude Publica do Acre"},{"author_name":"Andreia S Costa","author_inst":"Laboratorio Central de Saude Publica do Amapa"},{"author_name":"Marcia SP Cavalcante","author_inst":"Laboratorio Central de Saude Publica do Amapa"},{"author_name":"Marineide Souza Silva","author_inst":"Laboratorio Central de Saude Publica do Amazonas"},{"author_name":"Ilvanete A Silva","author_inst":"Laboratorio Central de Saude Publica do Para"},{"author_name":"Gleissy AL Borges","author_inst":"Laboratorio Central de Saude Publica do Para"},{"author_name":"Lidio G Lima","author_inst":"Laboratorio Central de Saude Publica do Maranhao"},{"author_name":"Hivylla LS Ferreira","author_inst":"Laboratorio Central de Saude Publica do Maranhao"},{"author_name":"Miriam TFP Livorati","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Andre L Abreu","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Arnaldo C Medeiros","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Hugo R Resque","author_inst":"Instituto Evandro Chagas"},{"author_name":"Rita CM Sousa","author_inst":"Programa de Pos Graduacao em Virologia - Instituto Evandro Chagas"},{"author_name":"Giselle MR Viana","author_inst":"Instituto Evandro Chagas"},{"author_name":"Michael Pride","author_inst":"Pfizer Inc."},{"author_name":"Ingrid Scully","author_inst":"Pfizer Inc."},{"author_name":"tara Ciolino","author_inst":"Pfizer Inc."},{"author_name":"Jennifer Obregon","author_inst":"Pfizer Inc."},{"author_name":"Michal Gazi","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Ricardo Carrion","author_inst":"University of Texas Medical Branch"},{"author_name":"Kendra Alfson","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Warren Kalina","author_inst":"Pfizer Inc."},{"author_name":"Deepak Kaushal","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Thorsten Klamp","author_inst":"BioNTech SE"},{"author_name":"Corinna Rosenbaum","author_inst":"BioNTech SE"},{"author_name":"Andreas Kuhn","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech SE"},{"author_name":"Philip Dormitzer","author_inst":"Pfizer Inc."},{"author_name":"Kathrin Jansen","author_inst":"Pfizer Inc."},{"author_name":"Ugur Sahin","author_inst":"BioNTech SE"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.09.04.20188771","rel_title":"COVID-19 Preprints and Their Publishing Rate: An Improved Method","rel_date":"2020-09-07","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.09.04.20188771","rel_abs":"Abstract Context: As the COVID-19 pandemic persists around the world, the scientific community continues to produce and circulate knowledge on the deadly disease at an unprecedented rate. During the early stage of the pandemic, preprints represented nearly 40% of all English-language COVID-19 scientific corpus (6,000+ preprints | 16,000+ articles). As of mid-August 2020, that proportion dropped to around 28% (13,000+ preprints | 49,000+ articles). Nevertheless, preprint servers remain a key engine in the efficient dissemination of scientific work on this infectious disease. But, giving the uncertified nature of the scientific manuscripts curated on preprint repositories, their integration to the global ecosystem of scientific communication is not without creating serious tensions. This is especially the case for biomedical knowledge since the dissemination of bad science can have widespread societal consequences. Scope: In this paper, I propose a robust method that allows the repeated monitoring and measuring of COVID-19 preprints' publication rate. I also introduce a new API called Upload-or-Publish. It is a free micro-API service that enables a client to query a specific preprint manuscript's publication status and associated meta-data using a unique ID. The beta-version is currently working and deployed. Data: I use Covid-19 Open Research Dataset (CORD-19) to calculate COVID-19 preprint corpus' conversion rate to peer-reviewed articles. CORD-19 dataset includes 10,454 preprints from arXiv, bioRxiv, and medRxiv. Methods: I utilize conditional fuzzy logic to link preprints with their published counterparts. My approach is an important departure from previous studies that rely exclusively on bio\/medRxiv API to ascertain preprints' publication status. This is problematic since the level of false negatives in bio\/medRxiv non-COVID-19 metadata could be as high as 37%. My analysis suggests bio\/medRxiv API accurately captures about only 50% of its published preprints. My improved method clocked an F1-score of 0.96. Findings: My analysis reveals that 19.6% (n=2048) of COVID-19 preprint manuscripts in the CORD-19 dataset uploaded on arXiv, bioRxiv, and medRxiv between January and early September 2020 were published in peer-reviewed venues. When compared to the most recent measure available, this represents a two-fold increase in a period of two months. My discussion review and theorize on the potential explanations for COVID-19 preprints' overall low conversion rate.","rel_num_authors":1,"rel_authors":[{"author_name":"Francois Lachapelle","author_inst":"University of British Columbia"},{"author_name":"Anjali J. Shastri","author_inst":"23andMe Inc., 223 N Mathilda Ave, Sunnyvale, CA 94086"},{"author_name":"Chelsea Ye","author_inst":"23andMe Inc., 223 N Mathilda Ave, Sunnyvale, CA 94086"},{"author_name":"Catherine H. Weldon","author_inst":"23andMe Inc., 223 N Mathilda Ave, Sunnyvale, CA 94086"},{"author_name":"Teresa Filshtein-Somnez","author_inst":"23andMe Inc., 223 N Mathilda Ave, Sunnyvale, CA 94086"},{"author_name":"Daniella Coker","author_inst":"23andMe Inc., 223 N Mathilda Ave, Sunnyvale, CA 94086"},{"author_name":"Antony Symons","author_inst":"23andMe Inc., 223 N Mathilda Ave, Sunnyvale, CA 94086"},{"author_name":"Jorge Esparza-Gordillo","author_inst":"Human genetics - R&D, GSK Medicines Research Centre, Target Sciences-R&D, Stevenage, UK"},{"author_name":"- The 23andMe COVID-19 Team","author_inst":""},{"author_name":"Stella Aslibekyan","author_inst":"23andMe Inc., 223 N Mathilda Ave, Sunnyvale, CA 94086"},{"author_name":"Adam Auton","author_inst":"23andMe Inc., 223 N Mathilda Ave, Sunnyvale, CA 94086"},{"author_name":"Jae Sun Park","author_inst":"Korea Centers for Disease Control & Prevention"},{"author_name":"Cheon-Kwon Yoo","author_inst":"Korea Centers for Disease Control & Prevention"},{"author_name":"Junyoung Kim","author_inst":"Korea Centers for Diseases Control and Prevention"},{"author_name":"Patricia S Lobo","author_inst":"Instituto Evandro Chagas"},{"author_name":"Fabiolla S Santos","author_inst":"Instituto Evandro Chagas"},{"author_name":"Alessandra AP Lima","author_inst":"Instituto Evandro Chagas"},{"author_name":"Camila M Bragagnolo","author_inst":"Instituto Evandro Chagas"},{"author_name":"Luana S Soares","author_inst":"Instituto Evandro Chagas"},{"author_name":"Patricia SM Almeida","author_inst":"Instituto Evandro Chagas"},{"author_name":"Darleise S Oliveira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Carolina KN Amorim","author_inst":"Instituto Evandro Chagas"},{"author_name":"Iran B Costa","author_inst":"Instituto Evandro Chagas"},{"author_name":"Dielle M Teixeira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Edvaldo T Penha Jr.","author_inst":"Instituto Evandro Chagas"},{"author_name":"Delana AM Bezerra","author_inst":"Instituto Evandro Chagas"},{"author_name":"Jones AM Siqueira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Fernando N Tavares","author_inst":"Instituto Evandro Chagas"},{"author_name":"Felipe B Freitas","author_inst":"Instituto Evandro Chagas"},{"author_name":"Janete TN Rodrigues","author_inst":"Laboratorio Central de Saude Publica do Acre"},{"author_name":"Janaina Mazaro","author_inst":"Laboratorio Central de Saude Publica do Acre"},{"author_name":"Andreia S Costa","author_inst":"Laboratorio Central de Saude Publica do Amapa"},{"author_name":"Marcia SP Cavalcante","author_inst":"Laboratorio Central de Saude Publica do Amapa"},{"author_name":"Marineide Souza Silva","author_inst":"Laboratorio Central de Saude Publica do Amazonas"},{"author_name":"Ilvanete A Silva","author_inst":"Laboratorio Central de Saude Publica do Para"},{"author_name":"Gleissy AL Borges","author_inst":"Laboratorio Central de Saude Publica do Para"},{"author_name":"Lidio G Lima","author_inst":"Laboratorio Central de Saude Publica do Maranhao"},{"author_name":"Hivylla LS Ferreira","author_inst":"Laboratorio Central de Saude Publica do Maranhao"},{"author_name":"Miriam TFP Livorati","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Andre L Abreu","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Arnaldo C Medeiros","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Hugo R Resque","author_inst":"Instituto Evandro Chagas"},{"author_name":"Rita CM Sousa","author_inst":"Programa de Pos Graduacao em Virologia - Instituto Evandro Chagas"},{"author_name":"Giselle MR Viana","author_inst":"Instituto Evandro Chagas"},{"author_name":"Michael Pride","author_inst":"Pfizer Inc."},{"author_name":"Ingrid Scully","author_inst":"Pfizer Inc."},{"author_name":"tara Ciolino","author_inst":"Pfizer Inc."},{"author_name":"Jennifer Obregon","author_inst":"Pfizer Inc."},{"author_name":"Michal Gazi","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Ricardo Carrion","author_inst":"University of Texas Medical Branch"},{"author_name":"Kendra Alfson","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Warren Kalina","author_inst":"Pfizer Inc."},{"author_name":"Deepak Kaushal","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Thorsten Klamp","author_inst":"BioNTech SE"},{"author_name":"Corinna Rosenbaum","author_inst":"BioNTech SE"},{"author_name":"Andreas Kuhn","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech SE"},{"author_name":"Philip Dormitzer","author_inst":"Pfizer Inc."},{"author_name":"Kathrin Jansen","author_inst":"Pfizer Inc."},{"author_name":"Ugur Sahin","author_inst":"BioNTech SE"}],"version":"1","license":"cc_by_nd","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.09.05.20188805","rel_title":"Health professionals practice and associated factors towards precautionary measures for COVID-19 pandemic in public health facilities of Gamo zone, southern Ethiopia: a cross-sectional study","rel_date":"2020-09-07","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.09.05.20188805","rel_abs":"Abstract Introduction Coronavirus disease-2019 (COVID-19) is a highly contagious acute respiratory disease, which caused by a novel coronavirus. The disease disrupts health systems and resulting in social, political, and economic crises. Health professionals are in front of this pandemic and always work in a high-risk environment. Currently, there is no vaccine or drug for the disease. Therefore, strictly practicing precautionary measures are the only option to save the life. Some studies reported health professional's practice of precautionary measures for COVID-19. Nevertheless, a few have identified factors affecting. As such, this study aimed to fill those research gaps in the study setting. Methods In this cross-sectional study, 428 health professionals were involved from the public health facilities of the Gamo zone, southern Ethiopia. A simple random sampling method was employed, and the data collected by the interviewer-administered Open Data Kit survey tool and observational checklist. The data analyzed in Stata version 15 and a binary logistic regression model used to identify factors. In this study, a statistically significant association was declared at P<0.05. Results In this study, 35{middle dot}3% (95%CI: 30{middle dot}7%, 39{middle dot}8%) of health professionals' had a good practice on precautionary measures for the COVID-19 pandemic. Use hand sanitizer or wash hands continuously with soap and water (68{middle dot}9%), cover nose and mouth with a tissue during sneezing or coughing (67{middle dot}3%), and use facemask in crowds (56{middle dot}8%) were the most common practice reported by study participants. Marital status, being married (AOR=1{middle dot}84, 95%CI: 1{middle dot}06, 3.18), good knowledge on the COVID-19 pandemic (AOR=2{middle dot}02, 95%CI: 1{middle dot}02, 3{middle dot}18), and positive attitude towards precautionary measures for COVID-19 were factors showed signification association with the practice. Conclusions The magnitude of good practice of precautionary measures for the COVID-19 pandemic among health professionals was low. As such, different interventions to improve the knowledge and attitude of health professionals in the health care system are highly needed to boost the practice and to advance service delivery.","rel_num_authors":8,"rel_authors":[{"author_name":"Abera Mersha","author_inst":"Arba Minch University"},{"author_name":"Shitaye Shibiru","author_inst":"Arba Minch University"},{"author_name":"Meseret Girma","author_inst":"Arba Minch University"},{"author_name":"Gistane Ayele","author_inst":"Arba Minch University"},{"author_name":"Agegnehu Bante","author_inst":"Arba Minch University"},{"author_name":"Mekidim Kassa","author_inst":"Arba Minch University"},{"author_name":"Sintayehu Abebe","author_inst":"Arba Minch University"},{"author_name":"Misgun Shewangizaw","author_inst":"Arba Minch University"},{"author_name":"- The 23andMe COVID-19 Team","author_inst":""},{"author_name":"Stella Aslibekyan","author_inst":"23andMe Inc., 223 N Mathilda Ave, Sunnyvale, CA 94086"},{"author_name":"Adam Auton","author_inst":"23andMe Inc., 223 N Mathilda Ave, Sunnyvale, CA 94086"},{"author_name":"Jae Sun Park","author_inst":"Korea Centers for Disease Control & Prevention"},{"author_name":"Cheon-Kwon Yoo","author_inst":"Korea Centers for Disease Control & Prevention"},{"author_name":"Junyoung Kim","author_inst":"Korea Centers for Diseases Control and Prevention"},{"author_name":"Patricia S Lobo","author_inst":"Instituto Evandro Chagas"},{"author_name":"Fabiolla S Santos","author_inst":"Instituto Evandro Chagas"},{"author_name":"Alessandra AP Lima","author_inst":"Instituto Evandro Chagas"},{"author_name":"Camila M Bragagnolo","author_inst":"Instituto Evandro Chagas"},{"author_name":"Luana S Soares","author_inst":"Instituto Evandro Chagas"},{"author_name":"Patricia SM Almeida","author_inst":"Instituto Evandro Chagas"},{"author_name":"Darleise S Oliveira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Carolina KN Amorim","author_inst":"Instituto Evandro Chagas"},{"author_name":"Iran B Costa","author_inst":"Instituto Evandro Chagas"},{"author_name":"Dielle M Teixeira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Edvaldo T Penha Jr.","author_inst":"Instituto Evandro Chagas"},{"author_name":"Delana AM Bezerra","author_inst":"Instituto Evandro Chagas"},{"author_name":"Jones AM Siqueira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Fernando N Tavares","author_inst":"Instituto Evandro Chagas"},{"author_name":"Felipe B Freitas","author_inst":"Instituto Evandro Chagas"},{"author_name":"Janete TN Rodrigues","author_inst":"Laboratorio Central de Saude Publica do Acre"},{"author_name":"Janaina Mazaro","author_inst":"Laboratorio Central de Saude Publica do Acre"},{"author_name":"Andreia S Costa","author_inst":"Laboratorio Central de Saude Publica do Amapa"},{"author_name":"Marcia SP Cavalcante","author_inst":"Laboratorio Central de Saude Publica do Amapa"},{"author_name":"Marineide Souza Silva","author_inst":"Laboratorio Central de Saude Publica do Amazonas"},{"author_name":"Ilvanete A Silva","author_inst":"Laboratorio Central de Saude Publica do Para"},{"author_name":"Gleissy AL Borges","author_inst":"Laboratorio Central de Saude Publica do Para"},{"author_name":"Lidio G Lima","author_inst":"Laboratorio Central de Saude Publica do Maranhao"},{"author_name":"Hivylla LS Ferreira","author_inst":"Laboratorio Central de Saude Publica do Maranhao"},{"author_name":"Miriam TFP Livorati","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Andre L Abreu","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Arnaldo C Medeiros","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Hugo R Resque","author_inst":"Instituto Evandro Chagas"},{"author_name":"Rita CM Sousa","author_inst":"Programa de Pos Graduacao em Virologia - Instituto Evandro Chagas"},{"author_name":"Giselle MR Viana","author_inst":"Instituto Evandro Chagas"},{"author_name":"Michael Pride","author_inst":"Pfizer Inc."},{"author_name":"Ingrid Scully","author_inst":"Pfizer Inc."},{"author_name":"tara Ciolino","author_inst":"Pfizer Inc."},{"author_name":"Jennifer Obregon","author_inst":"Pfizer Inc."},{"author_name":"Michal Gazi","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Ricardo Carrion","author_inst":"University of Texas Medical Branch"},{"author_name":"Kendra Alfson","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Warren Kalina","author_inst":"Pfizer Inc."},{"author_name":"Deepak Kaushal","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Thorsten Klamp","author_inst":"BioNTech SE"},{"author_name":"Corinna Rosenbaum","author_inst":"BioNTech SE"},{"author_name":"Andreas Kuhn","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech SE"},{"author_name":"Philip Dormitzer","author_inst":"Pfizer Inc."},{"author_name":"Kathrin Jansen","author_inst":"Pfizer Inc."},{"author_name":"Ugur Sahin","author_inst":"BioNTech SE"}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.09.04.20187088","rel_title":"Serological Responses to Human Virome Define Clinical Outcomes of Italian Patients Infected with SARS-CoV-2","rel_date":"2020-09-07","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.09.04.20187088","rel_abs":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the pandemic respiratory infectious disease COVID-19. However, clinical manifestations and outcomes differ significantly among COVID-19 patients, ranging from asymptomatic to extremely severe, and it remains unclear what drives these disparities. Here, we studied 159 hospitalized Italian patients with pneumonia from the NIAID-NCI COVID-19 Consortium using a phage-display method to characterize circulating antibodies binding to 93,904 viral peptides encoded by 1,276 strains of human viruses. SARS-CoV-2 infection was associated with a marked increase in individual's immune memory antibody repertoires linked to trajectories of disease severity from the longitudinal analysis also including anti-spike protein antibodies. By applying a machine-learning-based strategy, we developed a viral exposure signature predictive of COVID-19-related disease severity linked to patient survival. These results provide a basis for understanding the roles of memory B-cell repertoires in COVID-19-related symptoms as well as a predictive tool for monitoring its clinical severity.","rel_num_authors":13,"rel_authors":[{"author_name":"Limin Wang","author_inst":"National Cancer Institute"},{"author_name":"Julian Candia","author_inst":"National Cancer Institute"},{"author_name":"Lichun Ma","author_inst":"National Cancer Institute"},{"author_name":"Yongmei Zhao","author_inst":"National Cancer Institute"},{"author_name":"Luisa Imberti","author_inst":"ASST Spedali Civili di Brescia"},{"author_name":"Alessandra Sottini","author_inst":"ASST Spedali Civili di Brescia"},{"author_name":"Kerry Dobbs","author_inst":"National Institute of Allergy and Infectious Diseases"},{"author_name":"- NIAID-NCI COVID Consortium","author_inst":"-"},{"author_name":"Andrea Lisco","author_inst":"National Institute of Allergy and Infectious Diseases"},{"author_name":"Irini Sereti","author_inst":"National Institute of Allergy and Infectious Diseases"},{"author_name":"Helen C. Su","author_inst":"National Institute of Allergy and Infectious Diseases"},{"author_name":"Luigi D. Notarangelo","author_inst":"National Institute of Allergy and Infectious Diseases"},{"author_name":"Xin Wei Wang","author_inst":"National Cancer Institute"},{"author_name":"Junyoung Kim","author_inst":"Korea Centers for Diseases Control and Prevention"},{"author_name":"Patricia S Lobo","author_inst":"Instituto Evandro Chagas"},{"author_name":"Fabiolla S Santos","author_inst":"Instituto Evandro Chagas"},{"author_name":"Alessandra AP Lima","author_inst":"Instituto Evandro Chagas"},{"author_name":"Camila M Bragagnolo","author_inst":"Instituto Evandro Chagas"},{"author_name":"Luana S Soares","author_inst":"Instituto Evandro Chagas"},{"author_name":"Patricia SM Almeida","author_inst":"Instituto Evandro Chagas"},{"author_name":"Darleise S Oliveira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Carolina KN Amorim","author_inst":"Instituto Evandro Chagas"},{"author_name":"Iran B Costa","author_inst":"Instituto Evandro Chagas"},{"author_name":"Dielle M Teixeira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Edvaldo T Penha Jr.","author_inst":"Instituto Evandro Chagas"},{"author_name":"Delana AM Bezerra","author_inst":"Instituto Evandro Chagas"},{"author_name":"Jones AM Siqueira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Fernando N Tavares","author_inst":"Instituto Evandro Chagas"},{"author_name":"Felipe B Freitas","author_inst":"Instituto Evandro Chagas"},{"author_name":"Janete TN Rodrigues","author_inst":"Laboratorio Central de Saude Publica do Acre"},{"author_name":"Janaina Mazaro","author_inst":"Laboratorio Central de Saude Publica do Acre"},{"author_name":"Andreia S Costa","author_inst":"Laboratorio Central de Saude Publica do Amapa"},{"author_name":"Marcia SP Cavalcante","author_inst":"Laboratorio Central de Saude Publica do Amapa"},{"author_name":"Marineide Souza Silva","author_inst":"Laboratorio Central de Saude Publica do Amazonas"},{"author_name":"Ilvanete A Silva","author_inst":"Laboratorio Central de Saude Publica do Para"},{"author_name":"Gleissy AL Borges","author_inst":"Laboratorio Central de Saude Publica do Para"},{"author_name":"Lidio G Lima","author_inst":"Laboratorio Central de Saude Publica do Maranhao"},{"author_name":"Hivylla LS Ferreira","author_inst":"Laboratorio Central de Saude Publica do Maranhao"},{"author_name":"Miriam TFP Livorati","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Andre L Abreu","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Arnaldo C Medeiros","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Hugo R Resque","author_inst":"Instituto Evandro Chagas"},{"author_name":"Rita CM Sousa","author_inst":"Programa de Pos Graduacao em Virologia - Instituto Evandro Chagas"},{"author_name":"Giselle MR Viana","author_inst":"Instituto Evandro Chagas"},{"author_name":"Michael Pride","author_inst":"Pfizer Inc."},{"author_name":"Ingrid Scully","author_inst":"Pfizer Inc."},{"author_name":"tara Ciolino","author_inst":"Pfizer Inc."},{"author_name":"Jennifer Obregon","author_inst":"Pfizer Inc."},{"author_name":"Michal Gazi","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Ricardo Carrion","author_inst":"University of Texas Medical Branch"},{"author_name":"Kendra Alfson","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Warren Kalina","author_inst":"Pfizer Inc."},{"author_name":"Deepak Kaushal","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Thorsten Klamp","author_inst":"BioNTech SE"},{"author_name":"Corinna Rosenbaum","author_inst":"BioNTech SE"},{"author_name":"Andreas Kuhn","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech SE"},{"author_name":"Philip Dormitzer","author_inst":"Pfizer Inc."},{"author_name":"Kathrin Jansen","author_inst":"Pfizer Inc."},{"author_name":"Ugur Sahin","author_inst":"BioNTech SE"}],"version":"1","license":"cc0","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.09.04.20188532","rel_title":"Modeling COVID-19 dynamics in the sixteen West African countries","rel_date":"2020-09-07","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.09.04.20188532","rel_abs":"The COVID-19 pandemic is currently causing several damages to the world, especially in the public health sector. Due to identifiability problems in parameters' estimation of complex compartmental models, this study considered a simple deterministic susceptible-infectious-recovered (SIR)-type model to characterize and predict the future course of the pandemic in the West African countries. We estimated some specific characteristics of the disease's dynamics such as its initial conditions, reproduction numbers, true peak and peak of the reported cases, with their corresponding times, final epidemic size and time-varying attack ratio. Our findings revealed a relatively low proportion of susceptible individuals in the region and in the different countries (1:2% across West Africa). The detection rate of the disease was also relatively low (0:9% for West Africa as a whole) and < 2% for most countries, except for Gambia (12.5 %), Cape-Verde (9:5%), Mauritania (5:9%) and Ghana (4:4%). The reproduction number varied between 1.15 (Burkina-Faso) and 4.45 (Niger), and the peak time of the pandemic was between June and July for most countries. Generally, the peak time of the reported cases came a week (7-8 days) after the true peak time. The model predicted 222; 100 actual active cases in the region at the peak time, while the final epidemic size accounted for 0:6% of theWest African population (2; 526; 700 individuals). The results obtained showed that COVID-19 has not severely affected West Africa as noticed in other regions of the world. However, current control measures and standard operating procedures should be maintained over time to accelerate a decline in the observed trends of the pandemic.","rel_num_authors":3,"rel_authors":[{"author_name":"Sewanou H. Honfo","author_inst":"Laboratoire de Biomath\u00e9matiques et d'Estimations Foresti\u00e8res, Universit\u00e9 d'Abomey-Calavi"},{"author_name":"Beaugard H. Taboe","author_inst":"Laboratoire de Biomath\u00e9matiques et d'Estimations Foresti\u00e8s, Universit\u00e9 d'Abomey-Calavi"},{"author_name":"Romain Glele Kakai","author_inst":"Laboratoire de Biomath\u00e9matiques et d'Estimations Foresti\u00e8res, Universit\u00e9 d'Abomey-Calavi"},{"author_name":"Yongmei Zhao","author_inst":"National Cancer Institute"},{"author_name":"Luisa Imberti","author_inst":"ASST Spedali Civili di Brescia"},{"author_name":"Alessandra Sottini","author_inst":"ASST Spedali Civili di Brescia"},{"author_name":"Kerry Dobbs","author_inst":"National Institute of Allergy and Infectious Diseases"},{"author_name":"- NIAID-NCI COVID Consortium","author_inst":"-"},{"author_name":"Andrea Lisco","author_inst":"National Institute of Allergy and Infectious Diseases"},{"author_name":"Irini Sereti","author_inst":"National Institute of Allergy and Infectious Diseases"},{"author_name":"Helen C. Su","author_inst":"National Institute of Allergy and Infectious Diseases"},{"author_name":"Luigi D. Notarangelo","author_inst":"National Institute of Allergy and Infectious Diseases"},{"author_name":"Xin Wei Wang","author_inst":"National Cancer Institute"},{"author_name":"Junyoung Kim","author_inst":"Korea Centers for Diseases Control and Prevention"},{"author_name":"Patricia S Lobo","author_inst":"Instituto Evandro Chagas"},{"author_name":"Fabiolla S Santos","author_inst":"Instituto Evandro Chagas"},{"author_name":"Alessandra AP Lima","author_inst":"Instituto Evandro Chagas"},{"author_name":"Camila M Bragagnolo","author_inst":"Instituto Evandro Chagas"},{"author_name":"Luana S Soares","author_inst":"Instituto Evandro Chagas"},{"author_name":"Patricia SM Almeida","author_inst":"Instituto Evandro Chagas"},{"author_name":"Darleise S Oliveira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Carolina KN Amorim","author_inst":"Instituto Evandro Chagas"},{"author_name":"Iran B Costa","author_inst":"Instituto Evandro Chagas"},{"author_name":"Dielle M Teixeira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Edvaldo T Penha Jr.","author_inst":"Instituto Evandro Chagas"},{"author_name":"Delana AM Bezerra","author_inst":"Instituto Evandro Chagas"},{"author_name":"Jones AM Siqueira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Fernando N Tavares","author_inst":"Instituto Evandro Chagas"},{"author_name":"Felipe B Freitas","author_inst":"Instituto Evandro Chagas"},{"author_name":"Janete TN Rodrigues","author_inst":"Laboratorio Central de Saude Publica do Acre"},{"author_name":"Janaina Mazaro","author_inst":"Laboratorio Central de Saude Publica do Acre"},{"author_name":"Andreia S Costa","author_inst":"Laboratorio Central de Saude Publica do Amapa"},{"author_name":"Marcia SP Cavalcante","author_inst":"Laboratorio Central de Saude Publica do Amapa"},{"author_name":"Marineide Souza Silva","author_inst":"Laboratorio Central de Saude Publica do Amazonas"},{"author_name":"Ilvanete A Silva","author_inst":"Laboratorio Central de Saude Publica do Para"},{"author_name":"Gleissy AL Borges","author_inst":"Laboratorio Central de Saude Publica do Para"},{"author_name":"Lidio G Lima","author_inst":"Laboratorio Central de Saude Publica do Maranhao"},{"author_name":"Hivylla LS Ferreira","author_inst":"Laboratorio Central de Saude Publica do Maranhao"},{"author_name":"Miriam TFP Livorati","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Andre L Abreu","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Arnaldo C Medeiros","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Hugo R Resque","author_inst":"Instituto Evandro Chagas"},{"author_name":"Rita CM Sousa","author_inst":"Programa de Pos Graduacao em Virologia - Instituto Evandro Chagas"},{"author_name":"Giselle MR Viana","author_inst":"Instituto Evandro Chagas"},{"author_name":"Michael Pride","author_inst":"Pfizer Inc."},{"author_name":"Ingrid Scully","author_inst":"Pfizer Inc."},{"author_name":"tara Ciolino","author_inst":"Pfizer Inc."},{"author_name":"Jennifer Obregon","author_inst":"Pfizer Inc."},{"author_name":"Michal Gazi","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Ricardo Carrion","author_inst":"University of Texas Medical Branch"},{"author_name":"Kendra Alfson","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Warren Kalina","author_inst":"Pfizer Inc."},{"author_name":"Deepak Kaushal","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Thorsten Klamp","author_inst":"BioNTech SE"},{"author_name":"Corinna Rosenbaum","author_inst":"BioNTech SE"},{"author_name":"Andreas Kuhn","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech SE"},{"author_name":"Philip Dormitzer","author_inst":"Pfizer Inc."},{"author_name":"Kathrin Jansen","author_inst":"Pfizer Inc."},{"author_name":"Ugur Sahin","author_inst":"BioNTech SE"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"epidemiology"},{"rel_doi":"10.1101\/2020.09.04.20188326","rel_title":"Variations in state-level SARS-COV-2 testing recommendations in the United States, March-July 2020","rel_date":"2020-09-07","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.09.04.20188326","rel_abs":"Testing recommendations for COVID-19 in the United States have varied by state and over time in the spring and summer of 2020. As of July 2020, 16 states recommended testing asymptomatic members of the general public. The rate of COVID-19 tests reported in each state correlates with more permissive testing recommendations and with higher epidemic intensity. Higher per capita testing was associated with more complete reporting of COVID-19 deaths, which is a fundamental requirement for analyzing the pandemic. Coordinated, consistent guidelines for COVID-19 testing should be a high priority for state and national health systems.","rel_num_authors":2,"rel_authors":[{"author_name":"Stephanie R Perniciaro","author_inst":"Yale School of Public Health"},{"author_name":"Daniel M Weinberger","author_inst":"Yale School of Public Health"},{"author_name":"Romain Glele Kakai","author_inst":"Laboratoire de Biomath\u00e9matiques et d'Estimations Foresti\u00e8res, Universit\u00e9 d'Abomey-Calavi"},{"author_name":"Yongmei Zhao","author_inst":"National Cancer Institute"},{"author_name":"Luisa Imberti","author_inst":"ASST Spedali Civili di Brescia"},{"author_name":"Alessandra Sottini","author_inst":"ASST Spedali Civili di Brescia"},{"author_name":"Kerry Dobbs","author_inst":"National Institute of Allergy and Infectious Diseases"},{"author_name":"- NIAID-NCI COVID Consortium","author_inst":"-"},{"author_name":"Andrea Lisco","author_inst":"National Institute of Allergy and Infectious Diseases"},{"author_name":"Irini Sereti","author_inst":"National Institute of Allergy and Infectious Diseases"},{"author_name":"Helen C. Su","author_inst":"National Institute of Allergy and Infectious Diseases"},{"author_name":"Luigi D. Notarangelo","author_inst":"National Institute of Allergy and Infectious Diseases"},{"author_name":"Xin Wei Wang","author_inst":"National Cancer Institute"},{"author_name":"Junyoung Kim","author_inst":"Korea Centers for Diseases Control and Prevention"},{"author_name":"Patricia S Lobo","author_inst":"Instituto Evandro Chagas"},{"author_name":"Fabiolla S Santos","author_inst":"Instituto Evandro Chagas"},{"author_name":"Alessandra AP Lima","author_inst":"Instituto Evandro Chagas"},{"author_name":"Camila M Bragagnolo","author_inst":"Instituto Evandro Chagas"},{"author_name":"Luana S Soares","author_inst":"Instituto Evandro Chagas"},{"author_name":"Patricia SM Almeida","author_inst":"Instituto Evandro Chagas"},{"author_name":"Darleise S Oliveira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Carolina KN Amorim","author_inst":"Instituto Evandro Chagas"},{"author_name":"Iran B Costa","author_inst":"Instituto Evandro Chagas"},{"author_name":"Dielle M Teixeira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Edvaldo T Penha Jr.","author_inst":"Instituto Evandro Chagas"},{"author_name":"Delana AM Bezerra","author_inst":"Instituto Evandro Chagas"},{"author_name":"Jones AM Siqueira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Fernando N Tavares","author_inst":"Instituto Evandro Chagas"},{"author_name":"Felipe B Freitas","author_inst":"Instituto Evandro Chagas"},{"author_name":"Janete TN Rodrigues","author_inst":"Laboratorio Central de Saude Publica do Acre"},{"author_name":"Janaina Mazaro","author_inst":"Laboratorio Central de Saude Publica do Acre"},{"author_name":"Andreia S Costa","author_inst":"Laboratorio Central de Saude Publica do Amapa"},{"author_name":"Marcia SP Cavalcante","author_inst":"Laboratorio Central de Saude Publica do Amapa"},{"author_name":"Marineide Souza Silva","author_inst":"Laboratorio Central de Saude Publica do Amazonas"},{"author_name":"Ilvanete A Silva","author_inst":"Laboratorio Central de Saude Publica do Para"},{"author_name":"Gleissy AL Borges","author_inst":"Laboratorio Central de Saude Publica do Para"},{"author_name":"Lidio G Lima","author_inst":"Laboratorio Central de Saude Publica do Maranhao"},{"author_name":"Hivylla LS Ferreira","author_inst":"Laboratorio Central de Saude Publica do Maranhao"},{"author_name":"Miriam TFP Livorati","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Andre L Abreu","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Arnaldo C Medeiros","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Hugo R Resque","author_inst":"Instituto Evandro Chagas"},{"author_name":"Rita CM Sousa","author_inst":"Programa de Pos Graduacao em Virologia - Instituto Evandro Chagas"},{"author_name":"Giselle MR Viana","author_inst":"Instituto Evandro Chagas"},{"author_name":"Michael Pride","author_inst":"Pfizer Inc."},{"author_name":"Ingrid Scully","author_inst":"Pfizer Inc."},{"author_name":"tara Ciolino","author_inst":"Pfizer Inc."},{"author_name":"Jennifer Obregon","author_inst":"Pfizer Inc."},{"author_name":"Michal Gazi","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Ricardo Carrion","author_inst":"University of Texas Medical Branch"},{"author_name":"Kendra Alfson","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Warren Kalina","author_inst":"Pfizer Inc."},{"author_name":"Deepak Kaushal","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Thorsten Klamp","author_inst":"BioNTech SE"},{"author_name":"Corinna Rosenbaum","author_inst":"BioNTech SE"},{"author_name":"Andreas Kuhn","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech SE"},{"author_name":"Philip Dormitzer","author_inst":"Pfizer Inc."},{"author_name":"Kathrin Jansen","author_inst":"Pfizer Inc."},{"author_name":"Ugur Sahin","author_inst":"BioNTech SE"}],"version":"1","license":"cc_by_nc","type":"PUBLISHAHEADOFPRINT","category":"epidemiology"},{"rel_doi":"10.1101\/2020.09.04.20188359","rel_title":"COVID-19 superspreading in cities versus the countryside","rel_date":"2020-09-07","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.09.04.20188359","rel_abs":"So far, the COVID-19 pandemic has been characterised by an initial rapid rise in new cases followed by a peak and a more erratic behaviour that varies between regions. This is not easy to reproduce with traditional SIR models, which predict a more symmetric epidemic. Here, we argue that superspreaders and population heterogeneity are the core factors explaining this discrepancy. We do so through an agent-based lattice model of a disease spreading in a heterogeneous population.We predict that an epidemic driven by superspreaders will spread rapidly in cities, but not in the countryside where the sparse population limits the maximal number of secondary infections. This suggests that mitigation strategies should include restrictions on venues where people meet a largenumber of strangers. Furthermore, mitigating the epidemic in cities and in the countryside may require different levels of restrictions.","rel_num_authors":2,"rel_authors":[{"author_name":"Andreas Eilersen","author_inst":"University of Copenhagen"},{"author_name":"Kim Sneppen","author_inst":"University of Copenhagen"},{"author_name":"Romain Glele Kakai","author_inst":"Laboratoire de Biomath\u00e9matiques et d'Estimations Foresti\u00e8res, Universit\u00e9 d'Abomey-Calavi"},{"author_name":"Yongmei Zhao","author_inst":"National Cancer Institute"},{"author_name":"Luisa Imberti","author_inst":"ASST Spedali Civili di Brescia"},{"author_name":"Alessandra Sottini","author_inst":"ASST Spedali Civili di Brescia"},{"author_name":"Kerry Dobbs","author_inst":"National Institute of Allergy and Infectious Diseases"},{"author_name":"- NIAID-NCI COVID Consortium","author_inst":"-"},{"author_name":"Andrea Lisco","author_inst":"National Institute of Allergy and Infectious Diseases"},{"author_name":"Irini Sereti","author_inst":"National Institute of Allergy and Infectious Diseases"},{"author_name":"Helen C. Su","author_inst":"National Institute of Allergy and Infectious Diseases"},{"author_name":"Luigi D. Notarangelo","author_inst":"National Institute of Allergy and Infectious Diseases"},{"author_name":"Xin Wei Wang","author_inst":"National Cancer Institute"},{"author_name":"Junyoung Kim","author_inst":"Korea Centers for Diseases Control and Prevention"},{"author_name":"Patricia S Lobo","author_inst":"Instituto Evandro Chagas"},{"author_name":"Fabiolla S Santos","author_inst":"Instituto Evandro Chagas"},{"author_name":"Alessandra AP Lima","author_inst":"Instituto Evandro Chagas"},{"author_name":"Camila M Bragagnolo","author_inst":"Instituto Evandro Chagas"},{"author_name":"Luana S Soares","author_inst":"Instituto Evandro Chagas"},{"author_name":"Patricia SM Almeida","author_inst":"Instituto Evandro Chagas"},{"author_name":"Darleise S Oliveira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Carolina KN Amorim","author_inst":"Instituto Evandro Chagas"},{"author_name":"Iran B Costa","author_inst":"Instituto Evandro Chagas"},{"author_name":"Dielle M Teixeira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Edvaldo T Penha Jr.","author_inst":"Instituto Evandro Chagas"},{"author_name":"Delana AM Bezerra","author_inst":"Instituto Evandro Chagas"},{"author_name":"Jones AM Siqueira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Fernando N Tavares","author_inst":"Instituto Evandro Chagas"},{"author_name":"Felipe B Freitas","author_inst":"Instituto Evandro Chagas"},{"author_name":"Janete TN Rodrigues","author_inst":"Laboratorio Central de Saude Publica do Acre"},{"author_name":"Janaina Mazaro","author_inst":"Laboratorio Central de Saude Publica do Acre"},{"author_name":"Andreia S Costa","author_inst":"Laboratorio Central de Saude Publica do Amapa"},{"author_name":"Marcia SP Cavalcante","author_inst":"Laboratorio Central de Saude Publica do Amapa"},{"author_name":"Marineide Souza Silva","author_inst":"Laboratorio Central de Saude Publica do Amazonas"},{"author_name":"Ilvanete A Silva","author_inst":"Laboratorio Central de Saude Publica do Para"},{"author_name":"Gleissy AL Borges","author_inst":"Laboratorio Central de Saude Publica do Para"},{"author_name":"Lidio G Lima","author_inst":"Laboratorio Central de Saude Publica do Maranhao"},{"author_name":"Hivylla LS Ferreira","author_inst":"Laboratorio Central de Saude Publica do Maranhao"},{"author_name":"Miriam TFP Livorati","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Andre L Abreu","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Arnaldo C Medeiros","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Hugo R Resque","author_inst":"Instituto Evandro Chagas"},{"author_name":"Rita CM Sousa","author_inst":"Programa de Pos Graduacao em Virologia - Instituto Evandro Chagas"},{"author_name":"Giselle MR Viana","author_inst":"Instituto Evandro Chagas"},{"author_name":"Michael Pride","author_inst":"Pfizer Inc."},{"author_name":"Ingrid Scully","author_inst":"Pfizer Inc."},{"author_name":"tara Ciolino","author_inst":"Pfizer Inc."},{"author_name":"Jennifer Obregon","author_inst":"Pfizer Inc."},{"author_name":"Michal Gazi","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Ricardo Carrion","author_inst":"University of Texas Medical Branch"},{"author_name":"Kendra Alfson","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Warren Kalina","author_inst":"Pfizer Inc."},{"author_name":"Deepak Kaushal","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Thorsten Klamp","author_inst":"BioNTech SE"},{"author_name":"Corinna Rosenbaum","author_inst":"BioNTech SE"},{"author_name":"Andreas Kuhn","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech SE"},{"author_name":"Philip Dormitzer","author_inst":"Pfizer Inc."},{"author_name":"Kathrin Jansen","author_inst":"Pfizer Inc."},{"author_name":"Ugur Sahin","author_inst":"BioNTech SE"}],"version":"1","license":"cc_by","type":"PUBLISHAHEADOFPRINT","category":"epidemiology"},{"rel_doi":"10.1101\/2020.09.04.20188680","rel_title":"CAN EDUCATIONAL INSTITUTIONS REOPEN FOR IN-PERSON CLASSES SAFELY AMID THE COVID-19 PANDEMIC?","rel_date":"2020-09-07","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.09.04.20188680","rel_abs":"Research Context. Can educational institutions open up safely amid COVID-19? We build an epidemiological model to investigate the strategies necessary for institutions to safely reopen. The four measures that are most relevant for in-person opening are: (i) wide-spread rapid testing, possibly saliva-based, (ii) enforcement of mask-wearing, (iii) social distancing, and (iv) contact tracing. Research Design. Using an analytical setup, we theoretically demonstrate that institutions need to test at a relatively high level (e.g., at least once every week for all individuals) in the initial phases of reopening. Guided by the analytical setup, we derive insights from an agent-based simulation. Contact tracing is relatively more important when the positivity rate from random testing is relatively low, which is likely during the initial phases. An adaptive testing strategy based on positivity rates can help institutions optimally manage the costs and risks of reopening. Finally, to demonstrate the strategies in practice, we provide empirical estimates of some of the educational institutions opening up experience and comment on mitigation strategies. Empirically, we characterize the role of testing using data from the SHIELD program at the University of Illinois at Urbana Champaign (UIUC). Results. We show that increasing the testing levels from 0.2 per capita per day to 0.3 per capita per day can reduce the infectivity from 0.25 to 0.01, with an average slope of the infectivity to the testing curve being 0.35 in this range. We also cross-validate the results with data from a large number of universities in the United States, and show that institutions with higher levels of testing are associated with lower infections. The estimated marginal effect of increasing testing levels by 1% per capita per day across universities can reduce the positivity by an average of 0.0228% with a 99% confidence interval of [0.0209%, 0.0253%]. We also provide an estimate of the locational effects of institutions on mitigation strategies. We estimate from data on 228 different universities across the United States that an increase of infection rate at the county where a university is located by 1% has the potential to increase the institutional infection rate by an average of 0.14% with a 99% confidence interval of [0.032%, 0.248%] across all universities. This indicates that universities are not closed systems, rather they are open systems subject to external influence, and the extent of external influence potential is an important consideration for opening up of universities. Contributions. This paper contributes to the nascent literature on combating the COVID-19 pandemic and is especially relevant for large organizations. This work is motivated and guided by the SHIELD program of UIUC. We provide important policy pointers for the reopening of universities.","rel_num_authors":8,"rel_authors":[{"author_name":"Ujjal K Mukherjee","author_inst":"University of Illinois at Urbana-Champaign"},{"author_name":"Subhonmesh Bose","author_inst":"University of Illinois at Urbana-Champaign"},{"author_name":"Anton Ivanov","author_inst":"University of Illinois at Urbana-Champaign"},{"author_name":"Sebastian Souyris","author_inst":"University of Illinois at Urbana-Champaign"},{"author_name":"Sridhar Seshadri","author_inst":"University of Illinois at Urbana-Champaign"},{"author_name":"Padmavati Sridhar","author_inst":"University of California Berkeley"},{"author_name":"Ronald Watkins","author_inst":"University of Illinois at Urbana-Champaign"},{"author_name":"Yuqian Yu","author_inst":"University of Illinois at Urbana-Champaign"},{"author_name":"Andrea Lisco","author_inst":"National Institute of Allergy and Infectious Diseases"},{"author_name":"Irini Sereti","author_inst":"National Institute of Allergy and Infectious Diseases"},{"author_name":"Helen C. Su","author_inst":"National Institute of Allergy and Infectious Diseases"},{"author_name":"Luigi D. Notarangelo","author_inst":"National Institute of Allergy and Infectious Diseases"},{"author_name":"Xin Wei Wang","author_inst":"National Cancer Institute"},{"author_name":"Junyoung Kim","author_inst":"Korea Centers for Diseases Control and Prevention"},{"author_name":"Patricia S Lobo","author_inst":"Instituto Evandro Chagas"},{"author_name":"Fabiolla S Santos","author_inst":"Instituto Evandro Chagas"},{"author_name":"Alessandra AP Lima","author_inst":"Instituto Evandro Chagas"},{"author_name":"Camila M Bragagnolo","author_inst":"Instituto Evandro Chagas"},{"author_name":"Luana S Soares","author_inst":"Instituto Evandro Chagas"},{"author_name":"Patricia SM Almeida","author_inst":"Instituto Evandro Chagas"},{"author_name":"Darleise S Oliveira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Carolina KN Amorim","author_inst":"Instituto Evandro Chagas"},{"author_name":"Iran B Costa","author_inst":"Instituto Evandro Chagas"},{"author_name":"Dielle M Teixeira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Edvaldo T Penha Jr.","author_inst":"Instituto Evandro Chagas"},{"author_name":"Delana AM Bezerra","author_inst":"Instituto Evandro Chagas"},{"author_name":"Jones AM Siqueira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Fernando N Tavares","author_inst":"Instituto Evandro Chagas"},{"author_name":"Felipe B Freitas","author_inst":"Instituto Evandro Chagas"},{"author_name":"Janete TN Rodrigues","author_inst":"Laboratorio Central de Saude Publica do Acre"},{"author_name":"Janaina Mazaro","author_inst":"Laboratorio Central de Saude Publica do Acre"},{"author_name":"Andreia S Costa","author_inst":"Laboratorio Central de Saude Publica do Amapa"},{"author_name":"Marcia SP Cavalcante","author_inst":"Laboratorio Central de Saude Publica do Amapa"},{"author_name":"Marineide Souza Silva","author_inst":"Laboratorio Central de Saude Publica do Amazonas"},{"author_name":"Ilvanete A Silva","author_inst":"Laboratorio Central de Saude Publica do Para"},{"author_name":"Gleissy AL Borges","author_inst":"Laboratorio Central de Saude Publica do Para"},{"author_name":"Lidio G Lima","author_inst":"Laboratorio Central de Saude Publica do Maranhao"},{"author_name":"Hivylla LS Ferreira","author_inst":"Laboratorio Central de Saude Publica do Maranhao"},{"author_name":"Miriam TFP Livorati","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Andre L Abreu","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Arnaldo C Medeiros","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Hugo R Resque","author_inst":"Instituto Evandro Chagas"},{"author_name":"Rita CM Sousa","author_inst":"Programa de Pos Graduacao em Virologia - Instituto Evandro Chagas"},{"author_name":"Giselle MR Viana","author_inst":"Instituto Evandro Chagas"},{"author_name":"Michael Pride","author_inst":"Pfizer Inc."},{"author_name":"Ingrid Scully","author_inst":"Pfizer Inc."},{"author_name":"tara Ciolino","author_inst":"Pfizer Inc."},{"author_name":"Jennifer Obregon","author_inst":"Pfizer Inc."},{"author_name":"Michal Gazi","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Ricardo Carrion","author_inst":"University of Texas Medical Branch"},{"author_name":"Kendra Alfson","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Warren Kalina","author_inst":"Pfizer Inc."},{"author_name":"Deepak Kaushal","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Thorsten Klamp","author_inst":"BioNTech SE"},{"author_name":"Corinna Rosenbaum","author_inst":"BioNTech SE"},{"author_name":"Andreas Kuhn","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech SE"},{"author_name":"Philip Dormitzer","author_inst":"Pfizer Inc."},{"author_name":"Kathrin Jansen","author_inst":"Pfizer Inc."},{"author_name":"Ugur Sahin","author_inst":"BioNTech SE"}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"epidemiology"},{"rel_doi":"10.1101\/2020.09.04.20182998","rel_title":"Is climate a curse or a bless in the Covid-19 virus fighting?","rel_date":"2020-09-07","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.09.04.20182998","rel_abs":"Faced with the global pandemic of Covid-19, we need to better understand the links between meteorological factors and the virus and investigate the existence of potential seasonal patterns. In the vein of a recent empirical literature, we reassess the impact of weather factors on Covid-19 daily cases in a panel of advanced and emerging countries between January the first and 28th May 2020. We consider 5 different meteorological factors and go further previous studies. In addition, we give a short-run and medium\/long-run time perspective of the dramatic outcomes of the pandemic by both considering infected people (short-run) and fatalities (long-run). Our results reveal that the choice of delays and time perspective of the effects of climatic factors on the virus are crucial as well as Covid-19 outcomes can explain the discrepancies in the previous literature. For the first time, we use a dynamic panel model and consider two different kinds of channels between climate and Covid-19 virus: 1) direct\/physical factors related to the survivals and durability dynamics of the virus in surfaces and outdoors and 2) an indirect factor through human behaviors and individual mobility - walking or driving outdoors - to capture the impact of climate on social distancing and thus on Covid-19 outcomes. Our model is estimated \\emph{per se} two different estimators and persistence, delays in patterns, nonlinearities and numerous specifications changes are taken into account with many robustness checks. Our work reveal that temperatures and, more interestingly, solar radiation - that has been clearly undervalued in previous studies - are significant climatic drivers on Covid-19 outbreak. Indirect effects through human behaviors ie interrelationships between climatic variables and people mobility are significantly positive and should be considered to correctly assess the effects of climatic factors. Since climate is per se purely exogenous, climate tend to strengthen the effect of mobility on virus spread. The net effect from climate on Covid-19 outbreak will thus result from the direct negative effect of climatic variables and from the indirect effect due to the interaction between mobility and them. Direct negative effects from climatic factors on Covid-19 outcomes - when they are significant - are partly compensated by positive indirect effects through human mobility. Suitable control policies should be implemented to control the mobility and social distancing. \\\\","rel_num_authors":3,"rel_authors":[{"author_name":"Olivier DAMETTE","author_inst":"University of Lorraine, Climate Chair Paris Dauphine"},{"author_name":"Clement Mathonnat","author_inst":"University of Lorraine, BETA"},{"author_name":"Stephane Goutte","author_inst":"University Paris Saclay, UVSQ, CEMOTEV"},{"author_name":"Sebastian Souyris","author_inst":"University of Illinois at Urbana-Champaign"},{"author_name":"Sridhar Seshadri","author_inst":"University of Illinois at Urbana-Champaign"},{"author_name":"Padmavati Sridhar","author_inst":"University of California Berkeley"},{"author_name":"Ronald Watkins","author_inst":"University of Illinois at Urbana-Champaign"},{"author_name":"Yuqian Yu","author_inst":"University of Illinois at Urbana-Champaign"},{"author_name":"Andrea Lisco","author_inst":"National Institute of Allergy and Infectious Diseases"},{"author_name":"Irini Sereti","author_inst":"National Institute of Allergy and Infectious Diseases"},{"author_name":"Helen C. Su","author_inst":"National Institute of Allergy and Infectious Diseases"},{"author_name":"Luigi D. Notarangelo","author_inst":"National Institute of Allergy and Infectious Diseases"},{"author_name":"Xin Wei Wang","author_inst":"National Cancer Institute"},{"author_name":"Junyoung Kim","author_inst":"Korea Centers for Diseases Control and Prevention"},{"author_name":"Patricia S Lobo","author_inst":"Instituto Evandro Chagas"},{"author_name":"Fabiolla S Santos","author_inst":"Instituto Evandro Chagas"},{"author_name":"Alessandra AP Lima","author_inst":"Instituto Evandro Chagas"},{"author_name":"Camila M Bragagnolo","author_inst":"Instituto Evandro Chagas"},{"author_name":"Luana S Soares","author_inst":"Instituto Evandro Chagas"},{"author_name":"Patricia SM Almeida","author_inst":"Instituto Evandro Chagas"},{"author_name":"Darleise S Oliveira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Carolina KN Amorim","author_inst":"Instituto Evandro Chagas"},{"author_name":"Iran B Costa","author_inst":"Instituto Evandro Chagas"},{"author_name":"Dielle M Teixeira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Edvaldo T Penha Jr.","author_inst":"Instituto Evandro Chagas"},{"author_name":"Delana AM Bezerra","author_inst":"Instituto Evandro Chagas"},{"author_name":"Jones AM Siqueira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Fernando N Tavares","author_inst":"Instituto Evandro Chagas"},{"author_name":"Felipe B Freitas","author_inst":"Instituto Evandro Chagas"},{"author_name":"Janete TN Rodrigues","author_inst":"Laboratorio Central de Saude Publica do Acre"},{"author_name":"Janaina Mazaro","author_inst":"Laboratorio Central de Saude Publica do Acre"},{"author_name":"Andreia S Costa","author_inst":"Laboratorio Central de Saude Publica do Amapa"},{"author_name":"Marcia SP Cavalcante","author_inst":"Laboratorio Central de Saude Publica do Amapa"},{"author_name":"Marineide Souza Silva","author_inst":"Laboratorio Central de Saude Publica do Amazonas"},{"author_name":"Ilvanete A Silva","author_inst":"Laboratorio Central de Saude Publica do Para"},{"author_name":"Gleissy AL Borges","author_inst":"Laboratorio Central de Saude Publica do Para"},{"author_name":"Lidio G Lima","author_inst":"Laboratorio Central de Saude Publica do Maranhao"},{"author_name":"Hivylla LS Ferreira","author_inst":"Laboratorio Central de Saude Publica do Maranhao"},{"author_name":"Miriam TFP Livorati","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Andre L Abreu","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Arnaldo C Medeiros","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Hugo R Resque","author_inst":"Instituto Evandro Chagas"},{"author_name":"Rita CM Sousa","author_inst":"Programa de Pos Graduacao em Virologia - Instituto Evandro Chagas"},{"author_name":"Giselle MR Viana","author_inst":"Instituto Evandro Chagas"},{"author_name":"Michael Pride","author_inst":"Pfizer Inc."},{"author_name":"Ingrid Scully","author_inst":"Pfizer Inc."},{"author_name":"tara Ciolino","author_inst":"Pfizer Inc."},{"author_name":"Jennifer Obregon","author_inst":"Pfizer Inc."},{"author_name":"Michal Gazi","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Ricardo Carrion","author_inst":"University of Texas Medical Branch"},{"author_name":"Kendra Alfson","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Warren Kalina","author_inst":"Pfizer Inc."},{"author_name":"Deepak Kaushal","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Thorsten Klamp","author_inst":"BioNTech SE"},{"author_name":"Corinna Rosenbaum","author_inst":"BioNTech SE"},{"author_name":"Andreas Kuhn","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech SE"},{"author_name":"Philip Dormitzer","author_inst":"Pfizer Inc."},{"author_name":"Kathrin Jansen","author_inst":"Pfizer Inc."},{"author_name":"Ugur Sahin","author_inst":"BioNTech SE"}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"epidemiology"},{"rel_doi":"10.1101\/2020.09.04.20187914","rel_title":"Social capital and psychological distress during Colombian coronavirus disease lockdown","rel_date":"2020-09-07","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.09.04.20187914","rel_abs":"Introduction. This study aims to establish the association between low capital social (CS) with some indicators of psychological distress. Methods. A cross-sectional study was carried out using an online questionnaire that evaluated demographic variables, social capital, coronavirus disease perceived stress, depression risk, insomnia risk, and suicide risk. SC was taken as an independent variable, and symptoms indicating psychological distress was handed as dependent variables. Odds ratios (OR) were established with 95% confidence intervals (CI), using binary logistic regression analysis. Results. A group of 700 adults participated in the survey; they were aged between 18 and 76 years (M = 37, SD = 13). Low SC was associated with depression risk (OR = 2.00, 95%CI 1.34-2.97), elevated suicide risk (OR = 2.62, 95%CI 1.40-4.91) high perceived stress related to coronavirus disease (OR = 2.08, 95%CI 1.15-3.76), and insomnia risk (OR = 2.42, 95%CI 1.69-3.47). Conclusions. Low CS was associated with indicators of psychological distress represented in depression risk, elevated suicide risk, high perceived stress related to coronavirus disease and insomnia risk. SC is a community social resource that could help mitigate the impact of the coronavirus disease quarantine amidst the Colombian population's psychological health. It is necessary to deepen the SC role in psychological well-being during and after the coronavirus disease epidemic.","rel_num_authors":3,"rel_authors":[{"author_name":"Carmen Cecilia Caballero-Dominguez","author_inst":"Universidad del Magdalena, Santa Marta, Colombia"},{"author_name":"Jeimmy De Luque-Salcedo","author_inst":"Universidad del Magdalena, Santa Marta, Colombia"},{"author_name":"Adalberto Campo-Arias","author_inst":"Universidad del Magdalena, Santa Marta, Colombia"},{"author_name":"Sebastian Souyris","author_inst":"University of Illinois at Urbana-Champaign"},{"author_name":"Sridhar Seshadri","author_inst":"University of Illinois at Urbana-Champaign"},{"author_name":"Padmavati Sridhar","author_inst":"University of California Berkeley"},{"author_name":"Ronald Watkins","author_inst":"University of Illinois at Urbana-Champaign"},{"author_name":"Yuqian Yu","author_inst":"University of Illinois at Urbana-Champaign"},{"author_name":"Andrea Lisco","author_inst":"National Institute of Allergy and Infectious Diseases"},{"author_name":"Irini Sereti","author_inst":"National Institute of Allergy and Infectious Diseases"},{"author_name":"Helen C. Su","author_inst":"National Institute of Allergy and Infectious Diseases"},{"author_name":"Luigi D. Notarangelo","author_inst":"National Institute of Allergy and Infectious Diseases"},{"author_name":"Xin Wei Wang","author_inst":"National Cancer Institute"},{"author_name":"Junyoung Kim","author_inst":"Korea Centers for Diseases Control and Prevention"},{"author_name":"Patricia S Lobo","author_inst":"Instituto Evandro Chagas"},{"author_name":"Fabiolla S Santos","author_inst":"Instituto Evandro Chagas"},{"author_name":"Alessandra AP Lima","author_inst":"Instituto Evandro Chagas"},{"author_name":"Camila M Bragagnolo","author_inst":"Instituto Evandro Chagas"},{"author_name":"Luana S Soares","author_inst":"Instituto Evandro Chagas"},{"author_name":"Patricia SM Almeida","author_inst":"Instituto Evandro Chagas"},{"author_name":"Darleise S Oliveira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Carolina KN Amorim","author_inst":"Instituto Evandro Chagas"},{"author_name":"Iran B Costa","author_inst":"Instituto Evandro Chagas"},{"author_name":"Dielle M Teixeira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Edvaldo T Penha Jr.","author_inst":"Instituto Evandro Chagas"},{"author_name":"Delana AM Bezerra","author_inst":"Instituto Evandro Chagas"},{"author_name":"Jones AM Siqueira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Fernando N Tavares","author_inst":"Instituto Evandro Chagas"},{"author_name":"Felipe B Freitas","author_inst":"Instituto Evandro Chagas"},{"author_name":"Janete TN Rodrigues","author_inst":"Laboratorio Central de Saude Publica do Acre"},{"author_name":"Janaina Mazaro","author_inst":"Laboratorio Central de Saude Publica do Acre"},{"author_name":"Andreia S Costa","author_inst":"Laboratorio Central de Saude Publica do Amapa"},{"author_name":"Marcia SP Cavalcante","author_inst":"Laboratorio Central de Saude Publica do Amapa"},{"author_name":"Marineide Souza Silva","author_inst":"Laboratorio Central de Saude Publica do Amazonas"},{"author_name":"Ilvanete A Silva","author_inst":"Laboratorio Central de Saude Publica do Para"},{"author_name":"Gleissy AL Borges","author_inst":"Laboratorio Central de Saude Publica do Para"},{"author_name":"Lidio G Lima","author_inst":"Laboratorio Central de Saude Publica do Maranhao"},{"author_name":"Hivylla LS Ferreira","author_inst":"Laboratorio Central de Saude Publica do Maranhao"},{"author_name":"Miriam TFP Livorati","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Andre L Abreu","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Arnaldo C Medeiros","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Hugo R Resque","author_inst":"Instituto Evandro Chagas"},{"author_name":"Rita CM Sousa","author_inst":"Programa de Pos Graduacao em Virologia - Instituto Evandro Chagas"},{"author_name":"Giselle MR Viana","author_inst":"Instituto Evandro Chagas"},{"author_name":"Michael Pride","author_inst":"Pfizer Inc."},{"author_name":"Ingrid Scully","author_inst":"Pfizer Inc."},{"author_name":"tara Ciolino","author_inst":"Pfizer Inc."},{"author_name":"Jennifer Obregon","author_inst":"Pfizer Inc."},{"author_name":"Michal Gazi","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Ricardo Carrion","author_inst":"University of Texas Medical Branch"},{"author_name":"Kendra Alfson","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Warren Kalina","author_inst":"Pfizer Inc."},{"author_name":"Deepak Kaushal","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Thorsten Klamp","author_inst":"BioNTech SE"},{"author_name":"Corinna Rosenbaum","author_inst":"BioNTech SE"},{"author_name":"Andreas Kuhn","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech SE"},{"author_name":"Philip Dormitzer","author_inst":"Pfizer Inc."},{"author_name":"Kathrin Jansen","author_inst":"Pfizer Inc."},{"author_name":"Ugur Sahin","author_inst":"BioNTech SE"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"psychiatry and clinical psychology"},{"rel_doi":"10.1101\/2020.09.05.20187435","rel_title":"The dichotomous and incomplete adaptive immunity in COVID-19","rel_date":"2020-09-07","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.09.05.20187435","rel_abs":"The adaptive immunity that protects patients from coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is not well characterized. In particular, the asymptomatic patients have been found to induce weak and transient SARS-CoV-2 antibody responses, but the underlying mechanisms remain unknown; meanwhile, the protective immunity that guide the recovery of these asymptomatic patients is also not well studied. Here, we characterized SARS-CoV-2-specific B-cell and T-cell responses in 10 asymptomatic patients and 49 patients with other disease severity (mild, n=10, moderate, n=32, severe, n=7) and found that asymptomatic or mild symptomatic patients failed to mount virus-specific germinal center (GC) B cell responses that result in robust and long-term humoral immunity, assessed by GC response indicators including follicular helper T (TFH) cell and memory B cell responses as well as serum CXCL13 levels. Alternatively, these patients mounted potent virus-specific TH1 and CD8+ T cell responses. In sharp contrast, patients of moderate or severe disease induced vigorous virus-specific GC B cell responses and associated TFH responses; however, the virus-specific TH1 and CD8+ T cells were minimally induced in these patients. These results therefore uncovered the protective immunity in asymptomatic patients and revealed the strikingly dichotomous and unbalanced humoral and cellular immune responses in COVID-19 patients with different disease severity, providing important insights into rational design of COVID-19 vaccines.","rel_num_authors":16,"rel_authors":[{"author_name":"Leiqiong Gao","author_inst":"Institute of Immunology, Third Military Medical University, Chongqing 400038, China."},{"author_name":"Jing Zhou","author_inst":"Institute of Immunology, Third Military Medical University, Chongqing 400038, China."},{"author_name":"Sen Yang","author_inst":"Chongqing Public Health Medical Center, Chongqing 400038, China."},{"author_name":"Xiangyu Chen","author_inst":"Institute of Immunology, Third Military Medical University, Chongqing 400038, China."},{"author_name":"Yang Yang","author_inst":"Institute of Immunology, Third Military Medical University, Chongqing 400038, China."},{"author_name":"Ren Li","author_inst":"State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, Heilongjiang 150001, C"},{"author_name":"Zhiwei Pan","author_inst":"Institute of Immunology, Third Military Medical University, Chongqing 400038, China."},{"author_name":"Jing Zhao","author_inst":"Key Laboratory of Animal Epidemiology of the Ministry of Agriculture, College of Veterinary Medicine, China Agricultural University, Beijing 100193, China."},{"author_name":"Zhirong Li","author_inst":"Institute of Immunology, Third Military Medical University, Chongqing 400038, China."},{"author_name":"Qizhao Huang","author_inst":"Cancer Center, The General Hospital of Western Theater Command, Chengdu, Sichuan 610083, China."},{"author_name":"Jianfang Tang","author_inst":"Institute of Immunology, Third Military Medical University, Chongqing 400038, China."},{"author_name":"Li Hu","author_inst":"Institute of Immunology, Third Military Medical University, Chongqing 400038, China."},{"author_name":"Pinghuang Liu","author_inst":"Comparative Immunology Research Center, College of Veterinary Medicine, China Agricultural University, Beijing 100193, China."},{"author_name":"Guozhong Zhang","author_inst":"Key Laboratory of Animal Epidemiology of the Ministry of Agriculture, College of Veterinary Medicine, China Agricultural University, Beijing 100193, China."},{"author_name":"Yaokai Chen","author_inst":"Chongqing Public Health Medical Center, Chongqing 400038, China."},{"author_name":"Lilin Ye","author_inst":"1Institute of Immunology, Third Military Medical University, Chongqing 400038, China."},{"author_name":"Alessandra AP Lima","author_inst":"Instituto Evandro Chagas"},{"author_name":"Camila M Bragagnolo","author_inst":"Instituto Evandro Chagas"},{"author_name":"Luana S Soares","author_inst":"Instituto Evandro Chagas"},{"author_name":"Patricia SM Almeida","author_inst":"Instituto Evandro Chagas"},{"author_name":"Darleise S Oliveira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Carolina KN Amorim","author_inst":"Instituto Evandro Chagas"},{"author_name":"Iran B Costa","author_inst":"Instituto Evandro Chagas"},{"author_name":"Dielle M Teixeira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Edvaldo T Penha Jr.","author_inst":"Instituto Evandro Chagas"},{"author_name":"Delana AM Bezerra","author_inst":"Instituto Evandro Chagas"},{"author_name":"Jones AM Siqueira","author_inst":"Instituto Evandro Chagas"},{"author_name":"Fernando N Tavares","author_inst":"Instituto Evandro Chagas"},{"author_name":"Felipe B Freitas","author_inst":"Instituto Evandro Chagas"},{"author_name":"Janete TN Rodrigues","author_inst":"Laboratorio Central de Saude Publica do Acre"},{"author_name":"Janaina Mazaro","author_inst":"Laboratorio Central de Saude Publica do Acre"},{"author_name":"Andreia S Costa","author_inst":"Laboratorio Central de Saude Publica do Amapa"},{"author_name":"Marcia SP Cavalcante","author_inst":"Laboratorio Central de Saude Publica do Amapa"},{"author_name":"Marineide Souza Silva","author_inst":"Laboratorio Central de Saude Publica do Amazonas"},{"author_name":"Ilvanete A Silva","author_inst":"Laboratorio Central de Saude Publica do Para"},{"author_name":"Gleissy AL Borges","author_inst":"Laboratorio Central de Saude Publica do Para"},{"author_name":"Lidio G Lima","author_inst":"Laboratorio Central de Saude Publica do Maranhao"},{"author_name":"Hivylla LS Ferreira","author_inst":"Laboratorio Central de Saude Publica do Maranhao"},{"author_name":"Miriam TFP Livorati","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Andre L Abreu","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Arnaldo C Medeiros","author_inst":"Secretaria de Vigilancia em Saude"},{"author_name":"Hugo R Resque","author_inst":"Instituto Evandro Chagas"},{"author_name":"Rita CM Sousa","author_inst":"Programa de Pos Graduacao em Virologia - Instituto Evandro Chagas"},{"author_name":"Giselle MR Viana","author_inst":"Instituto Evandro Chagas"},{"author_name":"Michael Pride","author_inst":"Pfizer Inc."},{"author_name":"Ingrid Scully","author_inst":"Pfizer Inc."},{"author_name":"tara Ciolino","author_inst":"Pfizer Inc."},{"author_name":"Jennifer Obregon","author_inst":"Pfizer Inc."},{"author_name":"Michal Gazi","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Ricardo Carrion","author_inst":"University of Texas Medical Branch"},{"author_name":"Kendra Alfson","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Warren Kalina","author_inst":"Pfizer Inc."},{"author_name":"Deepak Kaushal","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Thorsten Klamp","author_inst":"BioNTech SE"},{"author_name":"Corinna Rosenbaum","author_inst":"BioNTech SE"},{"author_name":"Andreas Kuhn","author_inst":"BioNTech  RNA Pharmaceuticals GmbH"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech SE"},{"author_name":"Philip Dormitzer","author_inst":"Pfizer Inc."},{"author_name":"Kathrin Jansen","author_inst":"Pfizer Inc."},{"author_name":"Ugur Sahin","author_inst":"BioNTech SE"}],"version":"1","license":"cc_by_nc","type":"PUBLISHAHEADOFPRINT","category":"respiratory medicine"}]}



